<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Neuropsychopharmacology</journal-id><journal-title-group><journal-title>Neuropsychopharmacology</journal-title></journal-title-group><issn pub-type="ppub">0893-133X</issn><issn pub-type="epub">1740-634X</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22048466</article-id><article-id pub-id-type="pmc">3260990</article-id><article-id pub-id-type="pii">npp2011232</article-id><article-id pub-id-type="doi">10.1038/npp.2011.232</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Smoking Cessation Pharmacogenetics: Analysis of Varenicline and Bupropion in Placebo-Controlled Clinical Trials</article-title><alt-title alt-title-type="running">Pharmacogenetics of varenicline</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>King</surname><given-names>David P</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><contrib contrib-type="author"><name><surname>Paciga</surname><given-names>Sara</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Pickering</surname><given-names>Eve</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Benowitz</surname><given-names>Neal L</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Bierut</surname><given-names>Laura J</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Conti</surname><given-names>David V</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Kaprio</surname><given-names>Jaakko</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Lerman</surname><given-names>Caryn</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Peter W</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><aff id="aff1"><label>1</label><institution>Pfizer Global Research and Development</institution>, Groton, CT, <country>USA</country></aff><aff id="aff2"><label>2</label><institution>Division of Clinical Pharmacology, University of California at San Francisco</institution>, San Francisco, CA, <country>USA</country></aff><aff id="aff3"><label>3</label><institution>Department of Psychiatry, Washington University</institution>, St Louis, MO, <country>USA</country></aff><aff id="aff4"><label>4</label><institution>Department of Preventive Medicine, University of Southern California</institution>, Los Angeles, CA, <country>USA</country></aff><aff id="aff5"><label>5</label><institution>Department of Public Health, University of Helsinki</institution>, Helsinki, <country>Finland</country></aff><aff id="aff6"><label>6</label><institution>Department of Psychiatry, University of Pennsylvania</institution>, Philadelphia, PA, <country>USA</country></aff><aff id="aff7"><label>7</label><institution>Pfizer Global Pharmaceuticals</institution>, New York, NY, <country>USA</country></aff></contrib-group><author-notes><corresp id="caf1"><label>*</label><institution>Pfizer Global Research and Development</institution>, Eastern Point Road, MailStop 8200-2514, Groton, CT 06340, <country>USA</country>, Tel: +1 212 733 9255, Fax: +1 646 563 1684, E-mail: <email>davidpendletonking@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>02</month><year>2012</year></pub-date><pub-date pub-type="epub"><day>02</day><month>11</month><year>2011</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>2</month><year>2012</year></pub-date><volume>37</volume><issue>3</issue><fpage>641</fpage><lpage>650</lpage><history><date date-type="received"><day>31</day><month>03</month><year>2011</year></date><date date-type="rev-recd"><day>01</day><month>08</month><year>2011</year></date><date date-type="accepted"><day>10</day><month>08</month><year>2011</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2012 American College of Neuropsychopharmacology</copyright-statement><copyright-year>2012</copyright-year><copyright-holder>American College of Neuropsychopharmacology</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0/"><!--author-paid--><license-p>This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/</license-p></license></permissions><abstract><p>Despite effective therapies for smoking cessation, most smokers find quitting difficult and most successful quitters relapse. Considerable evidence supports a genetic risk for nicotine dependence; however, less is known about the pharmacogenetics of smoking cessation. In the first pharmacogenetic investigation of the efficacy of varenicline and bupropion, we examined whether genes important in the pharmacodynamics and pharmacokinetics of these drugs and nicotine predict medication efficacy and adverse events. Subjects participated in randomized, double-blind, placebo-controlled smoking cessation clinical trials, comparing varenicline, a nicotinic acetylcholine receptor (nAChR) partial agonist, with bupropion, a norepinephrine/dopamine reuptake inhibitor, and placebo. Primary analysis included 1175 smokers of European ancestry, and 785 single nucleotide polymorphisms from 24 genes, representing 254 linkage disequilibrium (LD) bins (genes included nAChR subunits, additional varenicline-specific genes, and genes involved in nicotine or bupropion metabolism). For varenicline, continuous abstinence (weeks 9&#x02013;12) was associated with multiple nAChR subunit genes (including <italic>CHRNB2</italic>, <italic>CHRNA5</italic>, and <italic>CHRNA4</italic>) (OR=1.76; 95&#x00025; CI: 1.23&#x02013;2.52) (<italic>p</italic>&#x0003c;0.005); for bupropion, abstinence was associated with <italic>CYP2B6</italic> (OR=1.78; 95&#x00025; CI: 1.27&#x02013;2.50) (<italic>p</italic>&#x0003c;0.001). Incidence of nausea was associated with several nAChR subunit genes (OR=0.50; 95&#x00025; CI: 0.36&#x02013;0.70) (<italic>p</italic>&#x0003c;0.0001) and time to relapse after quitting was associated with <italic>HTR3B</italic> (HR=1.97; 95&#x00025; CI: 1.45&#x02013;2.68) (<italic>p</italic>&#x0003c;0.0001). These data provide evidence for multiple genetic loci contributing to smoking cessation and therapeutic response. Different loci are associated with varenicline <italic>vs</italic> bupropion response, suggesting that additional research may identify clinically useful markers to guide treatment decisions.</p></abstract><kwd-group><kwd>varenicline</kwd><kwd>bupropion</kwd><kwd>pharmacogenetics</kwd><kwd>nicotine</kwd><kwd>nicotinic receptor</kwd><kwd>CYP2B6</kwd></kwd-group><kwd-group kwd-group-type="author-keywords"><kwd>pharmacogenetics/pharmacogenomics</kwd><kwd>addiction and substance abuse</kwd><kwd>clinical pharmacology/clinical trials</kwd><kwd>neuropharmacology</kwd><kwd>varenicline</kwd><kwd>bupropion</kwd><kwd>nicotine</kwd><kwd>smoking cessation</kwd><kwd>nicotinic receptors</kwd></kwd-group></article-meta></front><body><sec><title>INTRODUCTION</title><p>Nicotine dependence is a chronic, relapsing addiction (<xref ref-type="bibr" rid="bib32">Lerman <italic>et al</italic>, 2007</xref>), that afflicts &#x0003e;20&#x00025; of the population worldwide (<xref ref-type="bibr" rid="bib14">Fiore <italic>et al</italic>, 2008</xref>). Nicotine exerts its effect primarily at heterogeneous acetylcholine receptors (nAChRs) in the brain. This activity stimulates dopaminergic and other pathways and this increase in dopamine contributes to the rewarding effects of nicotine (<xref ref-type="bibr" rid="bib10">Dani and Heinemann, 1996</xref>). The principal subtypes of these pentameric receptors include <italic>&#x003b1;</italic>4 and <italic>&#x003b2;</italic>2 subunits, sometimes complimented by additional subunits of a different type (eg, <italic>&#x003b1;</italic>5) (<xref ref-type="bibr" rid="bib37">Mineur and Picciotto, 2008</xref>; <xref ref-type="bibr" rid="bib43">Ray <italic>et al</italic>, 2010</xref>). Nicotine shows high affinity for <italic>&#x003b1;</italic>4<italic>&#x003b2;</italic>2-containing nicotinic receptors, with <italic>K</italic><sub>i</sub> values in the low nanomolar range (<xref ref-type="bibr" rid="bib19">Gotti <italic>et al</italic>, 2006</xref>).</p><p>The persistence of smoking can be attributed to multiple diverse causes. Chief among these are genetic risk factors contributing to smoking behavior (<xref ref-type="bibr" rid="bib34">Li <italic>et al</italic>, 2003</xref>; <xref ref-type="bibr" rid="bib35">Maes <italic>et al</italic>, 2004</xref>; <xref ref-type="bibr" rid="bib49">Sullivan and Kendler, 1999</xref>; <xref ref-type="bibr" rid="bib50">The Tobacco and Genetics Consortium, 2010</xref>). Genome-wide association studies (GWAS) have identified a primary genetic locus on chromosome 15q25 that increases the likelihood of nicotine dependence by 30&#x02013;40&#x00025; in individuals who carry common risk alleles (<xref ref-type="bibr" rid="bib1">Amos <italic>et al</italic>, 2008</xref>; <xref ref-type="bibr" rid="bib23">Hung <italic>et al</italic>, 2008</xref>; <xref ref-type="bibr" rid="bib51">Thorgeirsson <italic>et al</italic>, 2008</xref>), as well as increasing the risk for several smoking-related diseases (<xref ref-type="bibr" rid="bib4">Broderick <italic>et al</italic>, 2009</xref>; <xref ref-type="bibr" rid="bib30">Landi <italic>et al</italic>, 2009</xref>; <xref ref-type="bibr" rid="bib42">Pillai <italic>et al</italic>, 2009</xref>; <xref ref-type="bibr" rid="bib51">Thorgeirsson <italic>et al</italic>, 2008</xref>). This locus includes three nicotinic receptor subunit genes (<italic>CHRNA5</italic>, <italic>CHRNB4</italic>, and <italic>CHRNA3</italic>), and a gene expressed in the lungs (<italic>IREB2</italic>), any (or several) of which may contain variants that contribute to nicotine dependence risk (<xref ref-type="bibr" rid="bib11">DeMeo <italic>et al</italic>, 2009</xref>). Indeed, evidence points to the presence of multiple independent polymorphisms associated with nicotine dependence (<xref ref-type="bibr" rid="bib46">Saccone <italic>et al</italic>, 2010a</xref>,&#x02009;<xref ref-type="bibr" rid="bib48">2010b</xref>). GWAS meta-analyses have identified four additional loci associated with nicotine dependence (<xref ref-type="bibr" rid="bib50">The Tobacco and Genetics Consortium, 2010</xref>; <xref ref-type="bibr" rid="bib52">Thorgeirsson <italic>et al</italic>, 2010</xref>). Two of these loci map close to additional nicotinic receptor subunits (<italic>CHRNA6</italic> and <italic>CHRNB3</italic>) and to enzymes important for the metabolism of nicotine (<italic>CYP2A6</italic> and <italic>CYP2B6</italic>).</p><p>An additional factor in the persistence of smoking behaviors is the difficulty in quitting. Although many methods have been developed that improve quit rates, none is effective in all smokers (<xref ref-type="bibr" rid="bib32">Lerman <italic>et al</italic>, 2007</xref>). Among these methods are several pharmacological agents, including nicotine replacement therapy (NRT), bupropion, and varenicline. Bupropion is a dopamine/norepinephrine reuptake inhibitor that also acts as a nicotinic receptor antagonist (<xref ref-type="bibr" rid="bib53">Warner and Shoaib, 2005</xref>); varenicline is a partial agonist of the <italic>&#x003b1;</italic>4<italic>&#x003b2;</italic>2 nAChR subtype (<xref ref-type="bibr" rid="bib7">Coe <italic>et al</italic>, 2005</xref>). The determinants of successful smoking cessation, like nicotine dependence itself, are likely to be diverse. The genetic components of successful smoking cessation are less well understood than nicotine dependence itself, although, like nicotine dependence, a significant proportion (&#x0223c;50&#x00025;) of the likelihood of quitting is genetic in origin (<xref ref-type="bibr" rid="bib5">Broms <italic>et al</italic>, 2006</xref>; <xref ref-type="bibr" rid="bib33">Lessov <italic>et al</italic>, 2004</xref>; <xref ref-type="bibr" rid="bib54">Xian <italic>et al</italic>, 2003</xref>), suggesting that specific genetic risk factors could be identified. Indeed, the chromosome 15q25 locus described above has been associated with successful quitting in pregnant women (<xref ref-type="bibr" rid="bib16">Freathy <italic>et al</italic>, 2009</xref>). However, many of the genetic loci affecting quitting are likely to be distinct from genetic determinants of nicotine dependence (<xref ref-type="bibr" rid="bib35">Maes <italic>et al</italic>, 2004</xref>; <xref ref-type="bibr" rid="bib50">The Tobacco and Genetics Consortium, 2010</xref>; <xref ref-type="bibr" rid="bib52">Thorgeirsson <italic>et al</italic>, 2010</xref>).</p><p>In order to better understand the genetic determinants of smoking cessation, recent pharmacogenetic studies have investigated genes that may impact nicotine or bupropion activity and metabolism, and also components of the dopaminergic system related to addiction (<xref ref-type="bibr" rid="bib8">Conti <italic>et al</italic>, 2008</xref>; <xref ref-type="bibr" rid="bib28">Kortmann <italic>et al</italic>, 2010</xref>; <xref ref-type="bibr" rid="bib31">Lee <italic>et al</italic>, 2007</xref>; <xref ref-type="bibr" rid="bib43">Ray <italic>et al</italic>, 2010</xref>). Although replications are needed, variants identified in <italic>CYP2B6</italic> and <italic>CHRNB2</italic> may influence cessation rates for bupropion (<xref ref-type="bibr" rid="bib8">Conti <italic>et al</italic>, 2008</xref>; <xref ref-type="bibr" rid="bib31">Lee <italic>et al</italic>, 2007</xref>), and variants in the choline acetyltransferase (<italic>CHAT</italic>) gene may influence the success of NRT (<xref ref-type="bibr" rid="bib43">Ray <italic>et al</italic>, 2010</xref>). In addition, several pharmacogenomics studies have investigated the effect of nicotine metabolism rates directly, through analysis of nicotine metabolites (<xref ref-type="bibr" rid="bib3">Benowitz, 2009</xref>) with reproducible associations with smoking cessation (<xref ref-type="bibr" rid="bib44">Ray <italic>et al</italic>, 2009</xref>).</p><p>Here, we describe the first pharmacogenetic analysis of smoking cessation in a large population of smokers derived from placebo-controlled clinical trials testing the efficacy of varenicline and bupropion. In addition to drug metabolizing and nicotinic receptor genes, we investigated the primary varenicline transporter (<italic>SLC22A2</italic>), additional genes in the chromosome 15q25 locus (<italic>IREB2</italic>, <italic>LOC123688</italic>, and <italic>PSMA4</italic>), and two serotonin receptors (<italic>HTR3A</italic> and <italic>HTR3B</italic>) whose expression in the gut may contribute to nausea while on varenicline treatment (<xref ref-type="bibr" rid="bib17">Gershon, 2004</xref>). We also examined whether variation in these candidate genes is associated with time to relapse to smoking or to nausea while on treatment.</p></sec><sec sec-type="methods"><title>PATIENTS AND METHODS</title><sec><title>Study Population</title><p>Subjects included in this study had participated in one of three randomized, double-blind, placebo-controlled smoking cessation clinical trials comparing varenicline, a nAChR partial agonist, with bupropion, a norepinephrine and dopamine reuptake inhibitor, and placebo (<xref ref-type="boxed-text" rid="box1">Box 1</xref>). The three trials have been described in detail previously (<xref ref-type="bibr" rid="bib18">Gonzales <italic>et al</italic>, 2006</xref>; <xref ref-type="bibr" rid="bib26">Jorenby <italic>et al</italic>, 2006</xref>; <xref ref-type="bibr" rid="bib39">Oncken <italic>et al</italic>, 2006</xref>). In brief, all of the studies included a 12-week treatment period and 40-week non-treatment follow-up. Participants were healthy men and women; all had smoked an average of at least 10 cigarettes per day (CPD) during the past year, with no period of abstinence longer than 3 months, and were motivated to quit. For these clinical trials, patients were excluded if they had a history of alcohol or other drug abuse or dependence in the previous 12 months. Clinical trial endpoints included carbon monoxide-confirmed continuous abstinence from weeks 9 to 12 and weeks 9 to 52 (<xref ref-type="bibr" rid="bib18">Gonzales <italic>et al</italic>, 2006</xref>; <xref ref-type="bibr" rid="bib26">Jorenby <italic>et al</italic>, 2006</xref>; <xref ref-type="bibr" rid="bib39">Oncken <italic>et al</italic>, 2006</xref>), and time to smoking relapse. Relapse to smoking after abstinence from weeks 9 to 12 was indicated either by patient-reported cigarette (as little as a single puff) or other nicotine use, or by an expiratory carbon monoxide measurement exceeding 10 p.p.m.</p><p>An optional blood sample was collected from clinical trial subjects for pharmacogenetic analysis to investigate potential associations between genetic variants and varenicline response and general characteristics of smoking cessation. Sample collection was not required for participation in the original clinical trials; however, &#x0003e;50&#x00025; of clinical trial subjects across all treatment arms volunteered to participate in the pharmacogenetic analysis.</p></sec><sec><title>Genotyping</title><p>Candidate genes of interest included the genes identified on Chr15q25 (including the <italic>CHRNA5</italic>, <italic>CHRNA3</italic>, and <italic>CHRNB4</italic> gene cluster), the remaining nAChR subunit genes, genes encoding the varenicline transporter (<italic>SLC22A2)</italic> and serotonergic targets hypothesized to be involved in varenicline-induced nausea (<italic>HTR3A, HTR3B)</italic>, as well as cytochrome P450 (CYP) genes involved in nicotine and bupropion metabolism (<xref ref-type="boxed-text" rid="box2">Box 2</xref>). Varenicline is highly selective for the <italic>&#x003b1;</italic>4<italic>&#x003b2;</italic>2 nicotinic receptor (Ki=0.17&#x02009;nM) (<xref ref-type="bibr" rid="bib41">Pfizer, 2010</xref>), but also shows moderate affinity (Ki=350&#x02009;nM) for the 5-HT<sub>3</sub> receptor and other common nicotinic receptors.</p><p>Primary genotyping was performed on the Illumina GoldenGate platform, with 975 candidate gene single-nucleotide polymorphisms (SNPs) and 216 ancestry informative marker SNPs. In addition, 89 complementary SNPs were genotyped using ABI Taqman and SNPlex methods. Genotyping call rates for all samples were &#x02a7e;94&#x00025; (mean=99.8&#x00025; median=99.8&#x00025;). Genotyping call rates for all SNPs were &#x02a7e;97&#x00025; (mean=99.8&#x00025;, median=99.9&#x00025;). SNPs were tested for Hardy&#x02013;Weinberg equilibrium. In total, 12 SNPs were significantly out of HWE (<italic>p</italic>&#x0003c;0.0001). None of these were associated with any phenotypes tested here. Multidimensional scaling analysis of the ancestry informative markers identified four subjects that did not cluster with the subjects of European ancestry. These subjects were excluded from the analysis.</p></sec><sec><title>Statistical Analysis</title><p>Genetic associations for continuous abstinence rates and nausea incidence were assessed using logistic regression, assuming an additive genetic model. A survival model was used to assess the relapse data; specifically, a proportional hazards model was fitted to determine whether the time to relapse was affected by genotype. The proportional hazards assumption was checked using plots of the log-log survival (relapse) curves. The relapse analysis also assumed an additive genetic model. Our analysis was limited to SNPs whose minor allele frequency was &#x0003e;5&#x00025; in our overall genotyped population, reducing the total number of candidate gene SNPs analyzed to 785. For each analysis, a treatment &#x000d7; genotype interaction term was initially included in the model. For markers with at least marginally significant interaction with treatment (<italic>p</italic>&#x0003c;0.20), the analysis was performed for each treatment group separately, as well as for all subjects together and adjusted for treatment. When the interaction was not significant, the data were analyzed as a single pooled sample, adjusted for treatment. To correct for multiple testing in which many markers were in strong linkage disequilibrium (LD), we selected individual SNPs representing bins of highly linked SNPs (<italic>r</italic><sup>2</sup>&#x0003e;0.8), with a single SNP for each bin included in a false discovery rate, multiple test correction approach (bins were derived from the Caucasian population described here). This reduced the total estimated number of independent tests from 785 to 254. All of the <italic>p</italic>-values reported here fell below a <italic>q</italic>-value of 0.2, using this approach.</p></sec></sec><sec><title>RESULTS</title><sec><title>Study Population</title><p>Across the three trials, 2699 patients were randomized to treatment (including 826 to varenicline 1.0&#x02009;mg twice per day titrated dose, 671 to bupropion, and 814 to placebo). DNA was extracted from blood samples of 1476 consenting individuals (524 varenicline; 440 bupropion; 512 placebo), and primary genetic analysis was performed on 1175 smokers of European ancestry. The genotyped subset was comparable to the overall clinical data set for baseline characteristics and outcomes, including age, gender, race, weight, smoking history, Fagerstr&#x000f6;m Test for Nicotine Dependence, therapeutic smoking cessation response (continuous abstinence from weeks 9 to 12), and adverse event profile (including nausea incidence with varenicline).</p></sec><sec><title>Baseline Characteristics</title><p>The demographic and smoking history characteristics of genotyped participants from the three clinical trials are shown in <xref rid="tbl1" ref-type="table">Table 1</xref>. Patients in the analysis had a mean age of approximately 43 years, and nearly 50&#x00025; of the population was female. They smoked on average 22 CPD (SD 9.4), and an average score of 5.3 on the Fagerstr&#x000f6;m Test for Nicotine Dependence (SD 2.1) indicated a moderate level of addiction. There were no significant differences in demographic variables or baseline characteristics across the three treatment groups.</p><p>Analysis of baseline smoking behavior among all genotyped subjects, as measured by the number of CPD, revealed a genetic association with the primary nicotine dependence locus on chromosome 15q25, indicating that the population studied here is consistent with previous populations evaluated for nicotine dependence (<xref ref-type="bibr" rid="bib51">Thorgeirsson <italic>et al</italic>, 2008</xref>). The most significant SNP detected in this region was rs4275821 (<italic>p</italic>&#x0003c;0.003), although we also detected nominal associations with other SNPs, including rs16969968 (<italic>p</italic>&#x0003c;0.03). The CPD association with the 15q25 region was detected in this population despite the absence of a full range of smoking phenotypes (individuals smoking &#x0003c;10 CPD were excluded from the clinical trials) (<xref ref-type="bibr" rid="bib18">Gonzales <italic>et al</italic>, 2006</xref>; <xref ref-type="bibr" rid="bib26">Jorenby <italic>et al</italic>, 2006</xref>; <xref ref-type="bibr" rid="bib39">Oncken <italic>et al</italic>, 2006</xref>). We also detected an association between the 15q25 locus and scores from the Fagerstr&#x000f6;m Test for Nicotine Dependence (<italic>p</italic>&#x0003c;0.004, rs12443170).</p></sec><sec><title>Continuous Abstinence</title><p>SNPs associated with continuous abstinence during weeks 9&#x02013;12 of the treatment period are shown in <xref rid="tbl2" ref-type="table">Table 2</xref>. Among the subjects randomized to varenicline treatment, two polymorphisms in <italic>CHRNB2</italic> (rs3811450 and rs4262952) were associated with the largest increased odds of continuous smoking abstinence from weeks 9 to 12 (OR=2.52 (CI: 1.32&#x02013;4.78); OR=2.44 (CI: 1.28&#x02013;4.63)). Additionally, there were significant associations of SNPs within the chromosome 15q25 locus, as well as the <italic>CHRNA4</italic> and <italic>CHRNA7</italic> gene loci. The SNP most significantly associated with continuous abstinence from weeks 9 to 12 in the varenicline-treated smokers, rs7164594, is within the 15q25 locus and is in strong LD with rs2036534 (<italic>r</italic><sup>2</sup>=0.98), a SNP previously determined to be significantly associated with lung cancer (<xref ref-type="bibr" rid="bib1">Amos <italic>et al</italic>, 2008</xref>) (<xref ref-type="fig" rid="fig1">Figure 1a</xref>).</p><p>Among the bupropion-treated subjects and in all three treatment groups combined, continuous abstinence at weeks 9&#x02013;12 was strongly associated with several SNPs in <italic>CYP2B6</italic> as well as two SNPs in <italic>CHRND</italic>, which encodes the nAChR delta subunit. Interestingly, one of the <italic>CYP2B6</italic> SNPs (rs8109525; <xref ref-type="fig" rid="fig1">Figure 1b</xref>) is contained within a LD bin that includes rs7260329, a SNP recently identified to be significantly associated with the number of cigarettes smoked per day (<xref ref-type="bibr" rid="bib52">Thorgeirsson <italic>et al</italic>, 2010</xref>). rs7260329 itself is nominally associated with continuous abstinence in the bupropion and combined populations, although to a lesser degree (<italic>p</italic>&#x0003c;0.008, <italic>p</italic>&#x0003c;0.02, respectively; <italic>q</italic> values &#x0003e;0.2). No SNP tested was significantly associated with abstinence on placebo treatment.</p><p>During longer-term follow-up, through 52 weeks, no polymorphism was significantly associated with continuous abstinence in the varenicline or placebo treatment groups. However, in the bupropion group, as well as in the three treatment groups combined, continuous abstinence was again associated with several SNPs within <italic>CYP2B6</italic> (<xref rid="tbl3" ref-type="table">Table 3</xref>), including rs8109525 (<italic>p</italic>=0.0028, <xref ref-type="fig" rid="fig1">Figure 1b</xref>). Several of the polymorphisms tested in <italic>CYP2B6</italic> were in LD with this SNP (including rs7260329, described above); however, none of these linked SNPs correspond to functionally described CYP2B6 alleles (<xref ref-type="bibr" rid="bib2">Anon, 2008</xref>). In the combined treatment group, variants in <italic>CYP2A6</italic> were also significantly associated with continued abstinence.</p></sec><sec><title>Relapse to Smoking, Following Successful Quitting, All Treatments</title><p>For all treatment groups combined, time to smoking relapse following initial abstinence from weeks 9&#x02013;12 was associated with SNPs in <italic>HTR3B</italic> (rs11606194, rs3758987) and <italic>HTR3A</italic> (rs11607240) (<xref rid="tbl4" ref-type="table">Table 4</xref>). <xref ref-type="fig" rid="fig2">Figure 2</xref> shows the time to relapse associated with the two most predictive SNPs, rs11606194 and rs3758987.</p></sec><sec><title>Nausea</title><p>In these clinical trials, the adverse event most commonly reported in patients receiving varenicline (1&#x02009;mg twice per day) was nausea (<xref ref-type="bibr" rid="bib18">Gonzales <italic>et al</italic>, 2006</xref>; <xref ref-type="bibr" rid="bib26">Jorenby <italic>et al</italic>, 2006</xref>; <xref ref-type="bibr" rid="bib39">Oncken <italic>et al</italic>, 2006</xref>). Nausea was reported by 30&#x00025; of individuals in the varenicline group (ranging from 28&#x00025; to 35&#x00025; across the three clinical trials) <italic>vs</italic> 10&#x00025; in the bupropion group, and 9&#x00025; in the placebo group. The incidence of nausea in the varenicline treatment group, and in all three treatment groups combined, was associated primarily with SNPs in the chromosome 15q25 locus (<xref rid="tbl5" ref-type="table">Table 5</xref> and <xref ref-type="supplementary-material" rid="sup1">Supplementary Table 1</xref>). Among varenicline-treated patients, nausea was most significantly associated with rs555018 in the <italic>CHRNA5</italic> gene (OR=1.62; 95&#x00025; CI: 1.19&#x02013;2.20) and rs1190449 in the <italic>CHRNG</italic> gene (OR=1.57; 95&#x00025; CI: 1.18&#x02013;2.08), while in the three treatment groups combined, the most significant association was with rs6495309 in the <italic>CHRNB4</italic> gene (OR=0.50; 95&#x00025; CI: 0.36&#x02013;0.70; <italic>p</italic>=4.04E&#x02013;05).</p></sec></sec><sec><title>DISCUSSION</title><p>This study represents the first genetic association study of varenicline for smoking cessation. The pharmacogenetic analysis, focusing largely on gene loci encoding nicotinic cholinergic receptor subunits and drug metabolizing enzymes, offers preliminary evidence that variants in <italic>CHRNA4</italic>, <italic>CHRNB2</italic>, and <italic>CHRNA7</italic> as well as in the 15q25 LD chromosomal region, including the nAChR genes <italic>CHRNA3</italic>, <italic>CHRNA5</italic>, and <italic>CHRNB4</italic>, influence the outcome (success or failure) of smoking cessation attempts with varenicline. In contrast, genetic analysis of response to bupropion suggests that the success of smoking cessation with this drug is determined in part by variation in <italic>CYP2B6</italic>, the gene encoding the primary enzyme responsible for the metabolism of bupropion (<xref ref-type="bibr" rid="bib13">Faucette <italic>et al</italic>, 2000</xref>), rather than by genetic variation in nicotinic cholinergic receptor pathways. In addition to smoking cessation pharmacogenetics, we also evaluated pharmacogenetic associations with the presence of nausea while attempting to quit smoking, as well as relapse to smoking following a successful period of continuous abstinence. As with response to varenicline, genetic variation in the nicotinic cholinergic receptor genes appears to contribute to the risk of experiencing nausea during smoking cessation, and interestingly, relapse to smoking was significantly associated with polymorphisms in the serotonergic receptor genes, <italic>HTR3A</italic> and <italic>HTR3B</italic>.</p><sec><title>Varenicline</title><p>Response to varenicline treatment is associated here with polymorphisms in multiple loci encoding nicotinic receptor subunits. Chief among these are the <italic>CHRNA4</italic> and <italic>CHRNB2</italic> loci, encoding the <italic>&#x003b1;</italic>4 and <italic>&#x003b2;</italic>2 nicotinic receptor subunits. Receptors comprised of these subunits are the specific targets of varenicline's activity, thus it is perhaps not surprising that these loci would be associated with varenicline response. In addition to these loci, there is also an association to varenicline response with polymorphisms in the chr15q25 locus. This, too, is consistent with varenicline activity, particularly given recent evidence demonstrating the importance of <italic>&#x003b1;</italic>5 subunits in predominantly <italic>&#x003b1;</italic>4<italic>&#x003b2;</italic>2 nicotinic receptors and the emergence of risk alleles in this locus as a primary factor in nicotine dependence (<xref ref-type="bibr" rid="bib15">Fowler <italic>et al</italic>, 2011</xref>; <xref ref-type="bibr" rid="bib29">Kuryatov <italic>et al</italic>, 2011</xref>; <xref ref-type="bibr" rid="bib55">Zheng <italic>et al</italic>, 2011</xref>). An association between the 15q25 locus and response to varenicline also supports an argument that response to varenicline is related to nicotine dependence itself. Due to the high degree of LD among loci in this region, it is difficult to discriminate causative loci. The positive markers for varenicline response are in LD (&#x0003e;0.6) with nicotine dependence markers (as well as markers for nausea; see below), thus these associations may be reflecting common functional alleles. In fact, the alleles that are associated with increased odds of quitting with varenicline are in LD with alleles associated with a decreased risk of nicotine dependence. This may be true of bupropion and placebo responders as well, although there are not sufficient subjects in these groups to detect such an effect. The relevance of the association with the <italic>CHRNA7</italic> locus is less clear, although varenicline does bind to homopentameric <italic>&#x003b1;</italic>7 nicotinic receptors (<xref ref-type="bibr" rid="bib7">Coe <italic>et al</italic>, 2005</xref>), however with reduced affinity in comparison with <italic>&#x003b1;</italic>4<italic>&#x003b2;</italic>2 receptors (<xref ref-type="bibr" rid="bib1">Amos <italic>et al</italic>, 2008</xref>; <xref ref-type="bibr" rid="bib23">Hung <italic>et al</italic>, 2008</xref>; <xref ref-type="bibr" rid="bib51">Thorgeirsson <italic>et al</italic>, 2008</xref>).</p><p>Previous pharmacogenetic studies of smoking cessation, focusing on bupropion treatment, also identified polymorphisms in <italic>CHRNB2</italic> associated with treatment response. In each of these studies, there is evidence to suggest that response to treatment in the placebo group may also be associated with <italic>CHRNB2</italic>, albeit to a lesser degree (<xref ref-type="bibr" rid="bib8">Conti <italic>et al</italic>, 2008</xref>; <xref ref-type="bibr" rid="bib20">Heitjan <italic>et al</italic>, 2008</xref>; <xref ref-type="bibr" rid="bib40">Perkins <italic>et al</italic>, 2009</xref>). In our study, we detect a similar, nominal association in our placebo group with a <italic>CHRNB2</italic> SNP (rs2072659, <italic>p</italic>=0.003, <italic>q</italic>=0.38). Thus, the genetic association of <italic>CHRNB2</italic> with response to varenicline might be explained in part by an increased likelihood to quit, regardless of treatment.</p></sec><sec><title>Bupropion</title><p>In our study, we observed an association between <italic>CYP2B6</italic> polymorphisms and response to bupropion treatment. <italic>CYP2B6</italic> is the primary metabolizing enzyme for bupropion (as well as a secondary enzyme for nicotine metabolism) thus the effectiveness of bupropion treatment in smoking cessation may be determined by the rate of its metabolism, as indicated by the <italic>CYP2B6</italic> genotype. This is consistent with previous studies, in which <italic>CYP2B6</italic> polymorphisms have been shown to affect the pharmacokinetics of bupropion (<xref ref-type="bibr" rid="bib27">Kirchheiner <italic>et al</italic>, 2003</xref>) and the likelihood of achieving abstinence with bupropion in smoking cessation trials (<xref ref-type="bibr" rid="bib31">Lee <italic>et al</italic>, 2007</xref>). However, the polymorphisms associated with response to bupropion in our study differed from those identified in previous studies (which were not successfully genotyped in our study), thus this does not represent a true replication. A better understanding of these associations may come from the identification and characterization of additional functional alleles affecting <italic>CYP2B6</italic> activity or expression.</p></sec><sec><title>Overall Quit Success at 1 Year</title><p>The nicotinic receptor polymorphisms associated with response to varenicline measured from weeks 9 to 12 were not associated with continuous abstinence through the non-treatment follow-up period (including all weeks 9&#x02013;52). During this period, no markers were significantly associated with continuous abstinence in the varenicline-treated smokers alone. In contrast, among the smokers treated with bupropion, <italic>CYP2B6</italic> polymorphisms were associated with continuous abstinence from weeks 9 to 52, as well as weeks 9 to 12. In fact, this association with <italic>CYP2B6</italic> polymorphisms extended to all smokers, regardless of treatment during the first 12 weeks. This may be due to a broader effect of <italic>CYP2B6</italic> on nicotine dependence, independent of its role in bupropion metabolism. This interpretation is consistent with a prior study identifying an association of a functional <italic>CYP2B6</italic> SNP with placebo response in a bupropion clinical trial (<xref ref-type="bibr" rid="bib31">Lee <italic>et al</italic>, 2007</xref>). Alternatively, this genetic signal, although more proximate to <italic>CYP2B6</italic>, may have a more direct effect on the adjacent <italic>CYP2A6</italic> locus, which is itself associated with continuous abstinence from weeks 9 to 52. In addition to (or perhaps because of) its role in nicotine metabolism, the <italic>CYP2A6</italic> locus has also recently been found to be genetically associated with nicotine dependence (<xref ref-type="bibr" rid="bib50">The Tobacco and Genetics Consortium, 2010</xref>; <xref ref-type="bibr" rid="bib52">Thorgeirsson <italic>et al</italic>, 2010</xref>), and phenotypic markers of nicotine metabolism rate have reproducible associations with prospective smoking cessation (<xref ref-type="bibr" rid="bib44">Ray <italic>et al</italic>, 2009</xref>). Continuous abstinence from weeks 9 to 52 also showed weaker associations with <italic>HTR3B</italic> and <italic>CHRNA10</italic> in the entire cohort. The association with <italic>HTR3B</italic> may be explained relative to its association with relapse to smoking (described below). The potential role of <italic>CHRN10A</italic> in smoking cessation is less clear, although it has been shown recently to be associated with nicotine dependence in an African-American population (<xref ref-type="bibr" rid="bib46">Saccone <italic>et al</italic>, 2010a</xref>,&#x02009;<xref ref-type="bibr" rid="bib48">2010b</xref>).</p></sec><sec><title>Relapse</title><p>We analyzed time to relapse to smoking in the subset of subjects who successfully quit smoking while on treatment during weeks 9&#x02013;12, but relapsed during weeks 13&#x02013;52. Unexpectedly, the strongest associations with this phenotype were with polymorphisms in genes encoding the serotonin receptors <italic>HTR3A</italic> and <italic>HTR3B</italic>. These genes were originally included in our study to test whether they might be related to nausea associated with varenicline treatment, although they are expressed widely in the brain as well as the gut (<xref ref-type="bibr" rid="bib38">Niesler <italic>et al</italic>, 2008</xref>). Previous investigations using an <italic>HTR3</italic> antagonist, ondansetron, provide some insights into why these loci may be important for relapse to smoking. This medicine, originally developed to prevent nausea (<xref ref-type="bibr" rid="bib9">Cubeddu <italic>et al</italic>, 1990</xref>), has been shown to lower cravings for alcohol and to ease the withdrawal symptoms of opioid addictions (<xref ref-type="bibr" rid="bib6">Chu <italic>et al</italic>, 2009</xref>; <xref ref-type="bibr" rid="bib25">Johnson <italic>et al</italic>, 2002</xref>). These results and our observations raise the intriguing possibility that this serotonin receptor family may be mediating its effects on relapse by impacting nicotine withdrawal symptoms, suggesting a potential role for HTR3 inhibition in reducing such withdrawal symptoms, regardless of the initial treatment method.</p></sec><sec><title>Nausea</title><p>In this study, the primary locus associated with nausea while attempting to quit smoking was the chr15q25 locus. This locus, which includes genes encoding the <italic>&#x003b2;</italic>4, <italic>&#x003b1;</italic>5, and <italic>&#x003b1;</italic>3 nicotinic receptor subunits (<italic>CHRNB4</italic>, <italic>CHRNA5</italic>, and <italic>CHRNA3</italic>), is the predominant locus associated with nicotine dependence (<xref ref-type="bibr" rid="bib1">Amos <italic>et al</italic>, 2008</xref>; <xref ref-type="bibr" rid="bib23">Hung <italic>et al</italic>, 2008</xref>; <xref ref-type="bibr" rid="bib51">Thorgeirsson <italic>et al</italic>, 2008</xref>). Carriers of risk alleles at this locus are 30&#x02013;40&#x00025; more likely to become nicotine dependent. As with the response to varenicline, the significant LD in this region suggests that these associations are likely to overlap with those for nicotine dependence, and thus nausea experienced while quitting may be directly related to nicotine dependence. Smokers who are more dependent smoke more cigarettes per day and have a higher daily intake of nicotine. The link between the chr15q25 locus genes and nausea may be explained by tolerance, such that those with a greater daily intake of nicotine are more tolerant and therefore experience less nausea in response to a nicotinic partial agonist such as varenicline. Alternatively, incidence of nausea may be elevated in subjects with greater risk for nicotine dependence because their nicotine intake is greater before quitting, therefore exacerbating the symptoms of withdrawal on quitting. SNPs associated with nausea are also linked to SNPs associated with the expression of CHRNA5, suggesting another mechanistic link between nicotine dependence and nausea on quitting. For subjects treated with varenicline, <italic>CHRNG</italic>, which encodes the nAChR&#x003b3; subunit, is also associated with nausea. The importance of this locus for nausea in the varenicline-treated subjects is not clear, although recent studies have identified associations with this region, which also includes the <italic>CHRND</italic> gene, and nicotine dependence (<xref ref-type="bibr" rid="bib47">Saccone <italic>et al</italic>, 2009</xref>), suggesting that the association with nausea may also be driven by nicotine dependence.</p></sec><sec><title>Strengths and Limitations of This Study</title><p>The recent successes of genome-wide genetic association studies have highlighted the need for large study populations in order to detect the small effect sizes often associated with common genetic polymorphisms. However, most pharmacogenomic studies conducted to date have involved relatively small sample populations (<xref ref-type="bibr" rid="bib22">Holmes <italic>et al</italic>, 2009</xref>). Thus, the strengths of this analysis include: (a) its large sample population&#x02014;the largest such study to date of bupropion for smoking cessation, the first (and therefore also largest) pharmacogenetic analysis of varenicline, and the first head-to-head analysis of these treatments; and (b) the availability of robust phenotypic data from three rigorously controlled clinical trials, providing a database of patient data, adverse events, and, importantly, carbon monoxide-confirmed smoking cessation outcomes. Limitations of this analysis include: (a) a lack of generalizability of the study findings to non-treatment-seeking smokers&#x02014;although the highly motivated (to quit smoking) population recruited to these trials is the subset of the broader smoking population to which pharmacogenetic tailoring approaches would be provided, efforts to encourage non-motivated smokers to quit may have different pharmacogenetic characteristics; and (b) a lack of ethnic diversity among the sample population&#x02014;the candidate gene analysis was limited to individuals of European ancestry in order to avoid the effects of population stratification, and the relatively small number of subjects of non-European descent in our population prevented meaningful analysis of this latter group. For this reason, the study findings may not apply to populations of non-European descent. These results will also require replication in independent populations for validation. Ideally, larger populations will also permit a genome-wide analysis of smoking cessation pharmacogenetics, which could identify additional novel loci affecting these phenotypes.</p></sec><sec><title>Future Perspectives</title><p>The goal of pharmacogenetic studies of smoking cessation therapy is to help increase the likelihood of an individual quitting smoking, and reduce the likelihood of adverse effects of smoking cessation therapy by individualizing treatment strategies according to genetic profile. Although pharmacogenetic tests for some conditions have had successful application in clinical practice (<xref ref-type="bibr" rid="bib36">Mallal <italic>et al</italic>, 2008</xref>; <xref ref-type="bibr" rid="bib45">Relling <italic>et al</italic>, 1999</xref>), this has not been without challenges (<xref ref-type="bibr" rid="bib21">Higgs <italic>et al</italic>, 2010</xref>; <xref ref-type="bibr" rid="bib24">Ikediobi <italic>et al</italic>, 2009</xref>). Even leaving aside issues of cost-effectiveness and concerns around tests that could result in effective therapies being withheld (<xref ref-type="bibr" rid="bib12">Epstein <italic>et al</italic>, 2009</xref>), several important issues need to be considered before pharmacogenetic testing for selection of smoking cessation treatment becomes standard clinical practice. Multiple genes and environmental factors probably combine to influence the response to smoking cessation therapies, yet most pharmacogenetic studies currently focus on a limited set of alleles and/or single genes and have limited power to account for gene&#x02013;gene and gene&#x02013;environment interactions. The development of effective individualized treatments for smoking cessation will likely require that future pharmacogenetic studies evaluate these multifactorial interactions. However, despite such challenges, access to larger populations and more detailed information regarding the molecular genetics of nicotine dependence and smoking cessation should lead to better optimization of cessation approaches, and to a reduction in overall smoking prevalence.</p></sec></sec><sec><title>CONCLUSIONS</title><p>These data provide both novel and supporting evidence for genetic loci contributing to smoking cessation and therapeutic response. Importantly, different genetic signals are associated with varenicline <italic>vs</italic> bupropion treatment response, suggesting that future research may lead to clinically useful markers to guide treatment decisions, resulting in improved smoking cessation rates overall, and a reduction in smoking prevalence.</p></sec></body><back><ack><p>Editorial support, in the form of collating review comments, proofreading, formatting of references, tables and figures, and styling the paper for submission, was provided by Geraldine Thompson, Abegale Templar, and Fiona Nitsche of UBC Scientific Solutions and was funded by Pfizer. Laura Bierut's research was supported by the National Institute of Health grant K02DA021237 (LJB) from the National Institute on Drug Abuse.</p></ack><fn-group><fn><p><xref ref-type="supplementary-material" rid="sup1">Supplementary Information</xref> accompanies the paper on the Neuropsychopharmacology website (http://www.nature.com/npp)</p></fn></fn-group><notes><p>This study was supported by Pfizer. David King, Sara Paciga, Eve Pickering, and Peter Park are or were employees of Pfizer. Laura Bierut is listed as an inventor on a patent &#x02018;Markers for Addiction' (US 20070258898), covering the use of certain SNPs in determining the diagnosis, prognosis, and treatment of addiction, and has acted as a consultant for Pfizer in 2008. David Conti acted as a consultant for Pfizer in 2008. Caryn Lerman has served as a consultant and/or has received research funding from GlaxoSmith-Kline, AstraZeneca, Pfizer, Targacept, and Novartis in the past 3 years. Neal Benowitz serves on Pfizer advisory boards related to varenicline and smoking cessation, as a paid consultant to other pharmaceutical companies developing smoking cessation medications, and has served as a paid expert witness in litigation against tobacco companies. Jaakko Kaprio has acted as a consultant for Pfizer in 2008, and has received funding for genetic analyses of nicotine dependence by a GRAND award, funded by Pfizer.</p></notes><ref-list><ref id="bib1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amos</surname><given-names>CI</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Broderick</surname><given-names>P</given-names></name><name><surname>Gorlov</surname><given-names>IP</given-names></name><name><surname>Gu</surname><given-names>J</given-names></name><name><surname>Eisen</surname><given-names>T</given-names></name><etal/></person-group><year>2008</year><article-title>Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1</article-title><source>Nat Genet</source><volume>40</volume><fpage>616</fpage><lpage>622</lpage><pub-id pub-id-type="pmid">18385676</pub-id></mixed-citation></ref><ref id="bib2"><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>Anon</collab></person-group><year>2008</year><article-title>CYP2B6 allele nomenclature</article-title>Available from:<x>
			
		</x><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.cypalleles.ki.se/cyp2b6.htm">http://www.cypalleles.ki.se/cyp2b6.htm</ext-link><x>
			.
		</x></mixed-citation></ref><ref id="bib3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benowitz</surname><given-names>NL</given-names></name></person-group><year>2009</year><article-title>Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics</article-title><source>Annu Rev Pharmacol Toxicol</source><volume>49</volume><fpage>57</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">18834313</pub-id></mixed-citation></ref><ref id="bib4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broderick</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Vijayakrishnan</surname><given-names>J</given-names></name><name><surname>Matakidou</surname><given-names>A</given-names></name><name><surname>Spitz</surname><given-names>MR</given-names></name><name><surname>Eisen</surname><given-names>T</given-names></name><etal/></person-group><year>2009</year><article-title>Deciphering the impact of common genetic variation on lung cancer risk: a genome-wide association study</article-title><source>Cancer Res</source><volume>69</volume><fpage>6633</fpage><lpage>6641</lpage><pub-id pub-id-type="pmid">19654303</pub-id></mixed-citation></ref><ref id="bib5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broms</surname><given-names>U</given-names></name><name><surname>Silventoinen</surname><given-names>K</given-names></name><name><surname>Madden</surname><given-names>PA</given-names></name><name><surname>Heath</surname><given-names>AC</given-names></name><name><surname>Kaprio</surname><given-names>J</given-names></name></person-group><year>2006</year><article-title>Genetic architecture of smoking behavior: a study of Finnish adult twins</article-title><source>Twin Res Hum Genet</source><volume>9</volume><fpage>64</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">16611469</pub-id></mixed-citation></ref><ref id="bib6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>LF</given-names></name><name><surname>Liang</surname><given-names>DY</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Sahbaie</surname><given-names>P</given-names></name><name><surname>D'Arcy</surname><given-names>N</given-names></name><name><surname>Liao</surname><given-names>G</given-names></name><etal/></person-group><year>2009</year><article-title>From mouse to man: the 5-HT3 receptor modulates physical dependence on opioid narcotics</article-title><source>Pharmacogenet Genomics</source><volume>19</volume><fpage>193</fpage><lpage>205</lpage><pub-id pub-id-type="pmid">19214139</pub-id></mixed-citation></ref><ref id="bib7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coe</surname><given-names>JW</given-names></name><name><surname>Brooks</surname><given-names>PR</given-names></name><name><surname>Vetelino</surname><given-names>MG</given-names></name><name><surname>Wirtz</surname><given-names>MC</given-names></name><name><surname>Arnold</surname><given-names>EP</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><etal/></person-group><year>2005</year><article-title>Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation</article-title><source>J Med Chem</source><volume>48</volume><fpage>3474</fpage><lpage>3477</lpage><pub-id pub-id-type="pmid">15887955</pub-id></mixed-citation></ref><ref id="bib8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conti</surname><given-names>DV</given-names></name><name><surname>Lee</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Van Den Berg</surname><given-names>D</given-names></name><name><surname>Thomas</surname><given-names>PD</given-names></name><etal/></person-group><year>2008</year><article-title>Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation</article-title><source>Hum Mol Genet</source><volume>17</volume><fpage>2834</fpage><lpage>2848</lpage><pub-id pub-id-type="pmid">18593715</pub-id></mixed-citation></ref><ref id="bib9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cubeddu</surname><given-names>LX</given-names></name><name><surname>Hoffmann</surname><given-names>IS</given-names></name><name><surname>Fuenmayor</surname><given-names>NT</given-names></name><name><surname>Finn</surname><given-names>AL</given-names></name></person-group><year>1990</year><article-title>Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting</article-title><source>N Engl J Med</source><volume>322</volume><fpage>810</fpage><lpage>816</lpage><pub-id pub-id-type="pmid">1689807</pub-id></mixed-citation></ref><ref id="bib10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dani</surname><given-names>JA</given-names></name><name><surname>Heinemann</surname><given-names>S</given-names></name></person-group><year>1996</year><article-title>Molecular and cellular aspects of nicotine abuse</article-title><source>Neuron</source><volume>16</volume><fpage>905</fpage><lpage>908</lpage><pub-id pub-id-type="pmid">8630247</pub-id></mixed-citation></ref><ref id="bib11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeMeo</surname><given-names>DL</given-names></name><name><surname>Mariani</surname><given-names>T</given-names></name><name><surname>Bhattacharya</surname><given-names>S</given-names></name><name><surname>Srisuma</surname><given-names>S</given-names></name><name><surname>Lange</surname><given-names>C</given-names></name><name><surname>Litonjua</surname><given-names>A</given-names></name><etal/></person-group><year>2009</year><article-title>Integration of genomic and genetic approaches implicates IREB2 as a COPD susceptibility gene</article-title><source>Am J Hum Genet</source><volume>85</volume><fpage>493</fpage><lpage>502</lpage><pub-id pub-id-type="pmid">19800047</pub-id></mixed-citation></ref><ref id="bib12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Epstein</surname><given-names>RS</given-names></name><name><surname>Frueh</surname><given-names>FW</given-names></name><name><surname>Geren</surname><given-names>D</given-names></name><name><surname>Hummer</surname><given-names>D</given-names></name><name><surname>McKibbin</surname><given-names>S</given-names></name><name><surname>O'Connor</surname><given-names>S</given-names></name><etal/></person-group><year>2009</year><article-title>Payer perspectives on pharmacogenomics testing and drug development</article-title><source>Pharmacogenomics</source><volume>10</volume><fpage>149</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">19102724</pub-id></mixed-citation></ref><ref id="bib13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faucette</surname><given-names>SR</given-names></name><name><surname>Hawke</surname><given-names>RL</given-names></name><name><surname>Lecluyse</surname><given-names>EL</given-names></name><name><surname>Shord</surname><given-names>SS</given-names></name><name><surname>Yan</surname><given-names>B</given-names></name><name><surname>Laethem</surname><given-names>RM</given-names></name><etal/></person-group><year>2000</year><article-title>Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity</article-title><source>Drug Metab Dispos</source><volume>28</volume><fpage>1222</fpage><lpage>1230</lpage><pub-id pub-id-type="pmid">10997944</pub-id></mixed-citation></ref><ref id="bib14"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Fiore</surname><given-names>MC</given-names></name><name><surname>Ja&#x000e9;n</surname><given-names>CR</given-names></name><name><surname>Baker</surname><given-names>TB</given-names></name><name><surname>Bailey</surname><given-names>WC</given-names></name><name><surname>Benowitz</surname><given-names>N</given-names></name><name><surname>Curry</surname><given-names>SJ</given-names></name><etal/></person-group><year>2008</year><source>Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Executive Summary</source><publisher-name>US Department of Health and Human Services. Public Health Service: Rockville MD</publisher-name>Available from:<x>
			
		</x><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ahrq.gov/path/tobacco.htm#clinic">http://www.ahrq.gov/path/tobacco.htm#clinic</ext-link><x>
			.
		</x></mixed-citation></ref><ref id="bib15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fowler</surname><given-names>CD</given-names></name><name><surname>Lu</surname><given-names>Q</given-names></name><name><surname>Johnson</surname><given-names>PM</given-names></name><name><surname>Marks</surname><given-names>MJ</given-names></name><name><surname>Kenny</surname><given-names>PJ</given-names></name></person-group><year>2011</year><article-title>Habenular alpha5 nicotinic receptor subunit signalling controls nicotine intake</article-title><source>Nature</source><volume>471</volume><fpage>597</fpage><lpage>601</lpage><pub-id pub-id-type="pmid">21278726</pub-id></mixed-citation></ref><ref id="bib16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freathy</surname><given-names>RM</given-names></name><name><surname>Ring</surname><given-names>SM</given-names></name><name><surname>Shields</surname><given-names>B</given-names></name><name><surname>Galobardes</surname><given-names>B</given-names></name><name><surname>Knight</surname><given-names>B</given-names></name><name><surname>Weedon</surname><given-names>MN</given-names></name><etal/></person-group><year>2009</year><article-title>A common genetic variant in the 15q24 nicotinic acetylcholine receptor gene cluster (CHRNA5-CHRNA3-CHRNB4) is associated with a reduced ability of women to quit smoking in pregnancy</article-title><source>Hum Mol Genet</source><volume>18</volume><fpage>2922</fpage><lpage>2927</lpage><pub-id pub-id-type="pmid">19429911</pub-id></mixed-citation></ref><ref id="bib17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gershon</surname><given-names>MD</given-names></name></person-group><year>2004</year><article-title>Review article: serotonin receptors and transporters&#x02014;roles in normal and abnormal gastrointestinal motility</article-title><source>Aliment Pharmacol Ther</source><volume>20</volume><supplement>(Suppl 7</supplement><fpage>3</fpage><lpage>14</lpage></mixed-citation></ref><ref id="bib18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzales</surname><given-names>D</given-names></name><name><surname>Rennard</surname><given-names>SI</given-names></name><name><surname>Nides</surname><given-names>M</given-names></name><name><surname>Oncken</surname><given-names>C</given-names></name><name><surname>Azoulay</surname><given-names>S</given-names></name><name><surname>Billing</surname><given-names>CB</given-names></name><etal/></person-group><year>2006</year><article-title>Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial</article-title><source>JAMA</source><volume>296</volume><fpage>47</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">16820546</pub-id></mixed-citation></ref><ref id="bib19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gotti</surname><given-names>C</given-names></name><name><surname>Zoli</surname><given-names>M</given-names></name><name><surname>Clementi</surname><given-names>F</given-names></name></person-group><year>2006</year><article-title>Brain nicotinic acetylcholine receptors: native subtypes and their relevance</article-title><source>Trends Pharmacol Sci</source><volume>27</volume><fpage>482</fpage><lpage>491</lpage><pub-id pub-id-type="pmid">16876883</pub-id></mixed-citation></ref><ref id="bib20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heitjan</surname><given-names>DF</given-names></name><name><surname>Guo</surname><given-names>M</given-names></name><name><surname>Ray</surname><given-names>R</given-names></name><name><surname>Wileyto</surname><given-names>EP</given-names></name><name><surname>Epstein</surname><given-names>LH</given-names></name><name><surname>Lerman</surname><given-names>C</given-names></name></person-group><year>2008</year><article-title>Identification of pharmacogenetic markers in smoking cessation therapy</article-title><source>Am J Med Genet B Neuropsychiatr Genet</source><volume>147B</volume><fpage>712</fpage><lpage>719</lpage><pub-id pub-id-type="pmid">18165968</pub-id></mixed-citation></ref><ref id="bib21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higgs</surname><given-names>J</given-names></name><name><surname>Gambhir</surname><given-names>N</given-names></name><name><surname>Ramsden</surname><given-names>SC</given-names></name><name><surname>Poulton</surname><given-names>K</given-names></name><name><surname>Newman</surname><given-names>WG</given-names></name></person-group><year>2010</year><article-title>Pharmacogenetic testing in the United Kingdom genetics and immunogenetics laboratories</article-title><source>Genet Test Mol Biomarkers</source><volume>14</volume><fpage>121</fpage><lpage>125</lpage><pub-id pub-id-type="pmid">20039783</pub-id></mixed-citation></ref><ref id="bib22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holmes</surname><given-names>MV</given-names></name><name><surname>Shah</surname><given-names>T</given-names></name><name><surname>Vickery</surname><given-names>C</given-names></name><name><surname>Smeeth</surname><given-names>L</given-names></name><name><surname>Hingorani</surname><given-names>AD</given-names></name><name><surname>Casas</surname><given-names>JP</given-names></name></person-group><year>2009</year><article-title>Fulfilling the promise of personalized medicine? Systematic review and field synopsis of pharmacogenetic studies</article-title><source>PLoS One</source><volume>4</volume><fpage>e7960</fpage><pub-id pub-id-type="pmid">19956635</pub-id></mixed-citation></ref><ref id="bib23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hung</surname><given-names>RJ</given-names></name><name><surname>McKay</surname><given-names>JD</given-names></name><name><surname>Gaborieau</surname><given-names>V</given-names></name><name><surname>Boffetta</surname><given-names>P</given-names></name><name><surname>Hashibe</surname><given-names>M</given-names></name><name><surname>Zaridze</surname><given-names>D</given-names></name><etal/></person-group><year>2008</year><article-title>A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25</article-title><source>Nature</source><volume>452</volume><fpage>633</fpage><lpage>637</lpage><pub-id pub-id-type="pmid">18385738</pub-id></mixed-citation></ref><ref id="bib24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikediobi</surname><given-names>ON</given-names></name><name><surname>Shin</surname><given-names>J</given-names></name><name><surname>Nussbaum</surname><given-names>RL</given-names></name><name><surname>Phillips</surname><given-names>KA</given-names></name><name><surname>Walsh</surname><given-names>JM</given-names></name><name><surname>Ladabaum</surname><given-names>U</given-names></name><etal/></person-group><year>2009</year><article-title>Addressing the challenges of the clinical application of pharmacogenetic testing</article-title><source>Clin Pharmacol Ther</source><volume>86</volume><fpage>28</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">19536122</pub-id></mixed-citation></ref><ref id="bib25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>BA</given-names></name><name><surname>Roache</surname><given-names>JD</given-names></name><name><surname>Ait-Daoud</surname><given-names>N</given-names></name><name><surname>Zanca</surname><given-names>NA</given-names></name><name><surname>Velazquez</surname><given-names>M</given-names></name></person-group><year>2002</year><article-title>Ondansetron reduces the craving of biologically predisposed alcoholics</article-title><source>Psychopharmacology (Berl)</source><volume>160</volume><fpage>408</fpage><lpage>413</lpage><pub-id pub-id-type="pmid">11919668</pub-id></mixed-citation></ref><ref id="bib26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jorenby</surname><given-names>DE</given-names></name><name><surname>Hays</surname><given-names>JT</given-names></name><name><surname>Rigotti</surname><given-names>NA</given-names></name><name><surname>Azoulay</surname><given-names>S</given-names></name><name><surname>Watsky</surname><given-names>EJ</given-names></name><name><surname>Williams</surname><given-names>KE</given-names></name><etal/></person-group><year>2006</year><article-title>Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial</article-title><source>JAMA</source><volume>296</volume><fpage>56</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">16820547</pub-id></mixed-citation></ref><ref id="bib27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirchheiner</surname><given-names>J</given-names></name><name><surname>Klein</surname><given-names>C</given-names></name><name><surname>Meineke</surname><given-names>I</given-names></name><name><surname>Sasse</surname><given-names>J</given-names></name><name><surname>Zanger</surname><given-names>UM</given-names></name><name><surname>Murdter</surname><given-names>TE</given-names></name><etal/></person-group><year>2003</year><article-title>Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6</article-title><source>Pharmacogenetics</source><volume>13</volume><fpage>619</fpage><lpage>626</lpage><pub-id pub-id-type="pmid">14515060</pub-id></mixed-citation></ref><ref id="bib28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kortmann</surname><given-names>GL</given-names></name><name><surname>Dobler</surname><given-names>CJ</given-names></name><name><surname>Bizarro</surname><given-names>L</given-names></name><name><surname>Bau</surname><given-names>CH</given-names></name></person-group><year>2010</year><article-title>Pharmacogenetics of smoking cessation therapy</article-title><source>Am J Med Genet B Neuropsychiatr Genet</source><volume>153B</volume><fpage>17</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">19475569</pub-id></mixed-citation></ref><ref id="bib29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuryatov</surname><given-names>A</given-names></name><name><surname>Berrettini</surname><given-names>W</given-names></name><name><surname>Lindstrom</surname><given-names>J</given-names></name></person-group><year>2011</year><article-title>Acetylcholine receptor (AChR) alpha5 subunit variant associated with risk for nicotine dependence and lung cancer reduces (alpha4beta2)alpha5 AChR function</article-title><source>Mol Pharmacol</source><volume>79</volume><fpage>119</fpage><lpage>125</lpage><pub-id pub-id-type="pmid">20881005</pub-id></mixed-citation></ref><ref id="bib30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landi</surname><given-names>MT</given-names></name><name><surname>Chatterjee</surname><given-names>N</given-names></name><name><surname>Yu</surname><given-names>K</given-names></name><name><surname>Goldin</surname><given-names>LR</given-names></name><name><surname>Goldstein</surname><given-names>AM</given-names></name><name><surname>Rotunno</surname><given-names>M</given-names></name><etal/></person-group><year>2009</year><article-title>A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma</article-title><source>Am J Hum Genet</source><volume>85</volume><fpage>679</fpage><lpage>691</lpage><pub-id pub-id-type="pmid">19836008</pub-id></mixed-citation></ref><ref id="bib31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>AM</given-names></name><name><surname>Jepson</surname><given-names>C</given-names></name><name><surname>Hoffmann</surname><given-names>E</given-names></name><name><surname>Epstein</surname><given-names>L</given-names></name><name><surname>Hawk</surname><given-names>LW</given-names></name><name><surname>Lerman</surname><given-names>C</given-names></name><etal/></person-group><year>2007</year><article-title>CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial</article-title><source>Biol Psychiatry</source><volume>62</volume><fpage>635</fpage><lpage>641</lpage><pub-id pub-id-type="pmid">17223085</pub-id></mixed-citation></ref><ref id="bib32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lerman</surname><given-names>C</given-names></name><name><surname>LeSage</surname><given-names>MG</given-names></name><name><surname>Perkins</surname><given-names>KA</given-names></name><name><surname>O'Malley</surname><given-names>SS</given-names></name><name><surname>Siegel</surname><given-names>SJ</given-names></name><name><surname>Benowitz</surname><given-names>NL</given-names></name><etal/></person-group><year>2007</year><article-title>Translational research in medication development for nicotine dependence</article-title><source>Nat Rev Drug Discov</source><volume>6</volume><fpage>746</fpage><lpage>762</lpage><pub-id pub-id-type="pmid">17690709</pub-id></mixed-citation></ref><ref id="bib33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lessov</surname><given-names>CN</given-names></name><name><surname>Martin</surname><given-names>NG</given-names></name><name><surname>Statham</surname><given-names>DJ</given-names></name><name><surname>Todorov</surname><given-names>AA</given-names></name><name><surname>Slutske</surname><given-names>WS</given-names></name><name><surname>Bucholz</surname><given-names>KK</given-names></name><etal/></person-group><year>2004</year><article-title>Defining nicotine dependence for genetic research: evidence from Australian twins</article-title><source>Psychol Med</source><volume>34</volume><fpage>865</fpage><lpage>879</lpage><pub-id pub-id-type="pmid">15500307</pub-id></mixed-citation></ref><ref id="bib34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>MD</given-names></name><name><surname>Ma</surname><given-names>JZ</given-names></name><name><surname>Cheng</surname><given-names>R</given-names></name><name><surname>Dupont</surname><given-names>RT</given-names></name><name><surname>Williams</surname><given-names>NJ</given-names></name><name><surname>Crews</surname><given-names>KM</given-names></name><etal/></person-group><year>2003</year><article-title>A genome-wide scan to identify loci for smoking rate in the Framingham Heart Study population</article-title><source>BMC Genet</source><volume>4</volume><supplement>(Suppl 1</supplement><fpage>S103</fpage><pub-id pub-id-type="pmid">14975171</pub-id></mixed-citation></ref><ref id="bib35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maes</surname><given-names>HH</given-names></name><name><surname>Sullivan</surname><given-names>PF</given-names></name><name><surname>Bulik</surname><given-names>CM</given-names></name><name><surname>Neale</surname><given-names>MC</given-names></name><name><surname>Prescott</surname><given-names>CA</given-names></name><name><surname>Eaves</surname><given-names>LJ</given-names></name><etal/></person-group><year>2004</year><article-title>A twin study of genetic and environmental influences on tobacco initiation, regular tobacco use and nicotine dependence</article-title><source>Psychol Med</source><volume>34</volume><fpage>1251</fpage><lpage>1261</lpage><pub-id pub-id-type="pmid">15697051</pub-id></mixed-citation></ref><ref id="bib36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mallal</surname><given-names>S</given-names></name><name><surname>Phillips</surname><given-names>E</given-names></name><name><surname>Carosi</surname><given-names>G</given-names></name><name><surname>Molina</surname><given-names>JM</given-names></name><name><surname>Workman</surname><given-names>C</given-names></name><name><surname>Tomazic</surname><given-names>J</given-names></name><etal/></person-group><year>2008</year><article-title>HLA-B<sup>&#x0002a;</sup>5701 screening for hypersensitivity to abacavir</article-title><source>N Engl J Med</source><volume>358</volume><fpage>568</fpage><lpage>579</lpage><pub-id pub-id-type="pmid">18256392</pub-id></mixed-citation></ref><ref id="bib37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mineur</surname><given-names>YS</given-names></name><name><surname>Picciotto</surname><given-names>MR</given-names></name></person-group><year>2008</year><article-title>Genetics of nicotinic acetylcholine receptors: relevance to nicotine addiction</article-title><source>Biochem Pharmacol</source><volume>75</volume><fpage>323</fpage><lpage>333</lpage><pub-id pub-id-type="pmid">17632086</pub-id></mixed-citation></ref><ref id="bib38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niesler</surname><given-names>B</given-names></name><name><surname>Kapeller</surname><given-names>J</given-names></name><name><surname>Hammer</surname><given-names>C</given-names></name><name><surname>Rappold</surname><given-names>G</given-names></name></person-group><year>2008</year><article-title>Serotonin type 3 receptor genes: HTR3A, B, C, D, E</article-title><source>Pharmacogenomics</source><volume>9</volume><fpage>501</fpage><lpage>504</lpage><pub-id pub-id-type="pmid">18466097</pub-id></mixed-citation></ref><ref id="bib39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oncken</surname><given-names>C</given-names></name><name><surname>Gonzales</surname><given-names>D</given-names></name><name><surname>Nides</surname><given-names>M</given-names></name><name><surname>Rennard</surname><given-names>S</given-names></name><name><surname>Watsky</surname><given-names>E</given-names></name><name><surname>Billing</surname><given-names>CB</given-names></name><etal/></person-group><year>2006</year><article-title>Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation</article-title><source>Arch Intern Med</source><volume>166</volume><fpage>1571</fpage><lpage>1577</lpage><pub-id pub-id-type="pmid">16908789</pub-id></mixed-citation></ref><ref id="bib40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perkins</surname><given-names>KA</given-names></name><name><surname>Lerman</surname><given-names>C</given-names></name><name><surname>Mercincavage</surname><given-names>M</given-names></name><name><surname>Fonte</surname><given-names>CA</given-names></name><name><surname>Briski</surname><given-names>JL</given-names></name></person-group><year>2009</year><article-title>Nicotinic acetylcholine receptor beta2 subunit (CHRNB2) gene and short-term ability to quit smoking in response to nicotine patch</article-title><source>Cancer Epidemiol Biomarkers Prev</source><volume>18</volume><fpage>2608</fpage><lpage>2612</lpage><pub-id pub-id-type="pmid">19755656</pub-id></mixed-citation></ref><ref id="bib41"><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>Pfizer</collab></person-group><year>2010</year><source>Chantix (Varenicline) Tablets. Prescribing Information</source><publisher-name>Pfizer: New York, NY</publisher-name>Available from:<x>
			
		</x><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.pfizer.com/files/products/uspi_chantix.pdf">http://www.pfizer.com/files/products/uspi_chantix.pdf</ext-link><x>
			.
		</x></mixed-citation></ref><ref id="bib42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pillai</surname><given-names>SG</given-names></name><name><surname>Ge</surname><given-names>D</given-names></name><name><surname>Zhu</surname><given-names>G</given-names></name><name><surname>Kong</surname><given-names>X</given-names></name><name><surname>Shianna</surname><given-names>KV</given-names></name><name><surname>Need</surname><given-names>AC</given-names></name><etal/></person-group><year>2009</year><article-title>A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci</article-title><source>PLoS Genet</source><volume>5</volume><fpage>e1000421</fpage><pub-id pub-id-type="pmid">19300482</pub-id></mixed-citation></ref><ref id="bib43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ray</surname><given-names>R</given-names></name><name><surname>Mitra</surname><given-names>N</given-names></name><name><surname>Baldwin</surname><given-names>D</given-names></name><name><surname>Guo</surname><given-names>M</given-names></name><name><surname>Patterson</surname><given-names>F</given-names></name><name><surname>Heitjan</surname><given-names>DF</given-names></name><etal/></person-group><year>2010</year><article-title>Convergent evidence that choline acetyltransferase gene variation is associated with prospective smoking cessation and nicotine dependence</article-title><source>Neuropsychopharmacology</source><volume>35</volume><fpage>1374</fpage><lpage>1382</lpage><pub-id pub-id-type="pmid">20147892</pub-id></mixed-citation></ref><ref id="bib44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ray</surname><given-names>R</given-names></name><name><surname>Tyndale</surname><given-names>RF</given-names></name><name><surname>Lerman</surname><given-names>C</given-names></name></person-group><year>2009</year><article-title>Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes</article-title><source>J Neurogenet</source><volume>23</volume><fpage>252</fpage><lpage>261</lpage><pub-id pub-id-type="pmid">19169923</pub-id></mixed-citation></ref><ref id="bib45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Relling</surname><given-names>MV</given-names></name><name><surname>Hancock</surname><given-names>ML</given-names></name><name><surname>Rivera</surname><given-names>GK</given-names></name><name><surname>Sandlund</surname><given-names>JT</given-names></name><name><surname>Ribeiro</surname><given-names>RC</given-names></name><name><surname>Krynetski</surname><given-names>EY</given-names></name><etal/></person-group><year>1999</year><article-title>Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus</article-title><source>J Natl Cancer Inst</source><volume>91</volume><fpage>2001</fpage><lpage>2008</lpage><pub-id pub-id-type="pmid">10580024</pub-id></mixed-citation></ref><ref id="bib46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saccone</surname><given-names>NL</given-names></name><name><surname>Culverhouse</surname><given-names>RC</given-names></name><name><surname>Schwantes-An</surname><given-names>TH</given-names></name><name><surname>Cannon</surname><given-names>DS</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Cichon</surname><given-names>S</given-names></name><etal/></person-group><year>2010a</year><article-title>Multiple independent loci at chromosome 15q25.1 affect smoking quantity: a meta-analysis and comparison with lung cancer and COPD</article-title><source>PLoS Genet</source><volume>6</volume><lpage>e1001053</lpage></mixed-citation></ref><ref id="bib47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saccone</surname><given-names>NL</given-names></name><name><surname>Saccone</surname><given-names>SF</given-names></name><name><surname>Hinrichs</surname><given-names>AL</given-names></name><name><surname>Stitzel</surname><given-names>JA</given-names></name><name><surname>Duan</surname><given-names>W</given-names></name><name><surname>Pergadia</surname><given-names>ML</given-names></name><etal/></person-group><year>2009</year><article-title>Multiple distinct risk loci for nicotine dependence identified by dense coverage of the complete family of nicotinic receptor subunit (CHRN) genes</article-title><source>Am J Med Genet B Neuropsychiatr Genet</source><volume>150B</volume><fpage>453</fpage><lpage>466</lpage><pub-id pub-id-type="pmid">19259974</pub-id></mixed-citation></ref><ref id="bib48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saccone</surname><given-names>NL</given-names></name><name><surname>Schwantes-An</surname><given-names>TH</given-names></name><name><surname>Wang</surname><given-names>JC</given-names></name><name><surname>Grucza</surname><given-names>RA</given-names></name><name><surname>Breslau</surname><given-names>N</given-names></name><name><surname>Hatsukami</surname><given-names>D</given-names></name><etal/></person-group><year>2010b</year><article-title>Multiple cholinergic nicotinic receptor genes affect nicotine dependence risk in African and European Americans</article-title><source>Genes Brain Behav</source><volume>9</volume><fpage>741</fpage><lpage>750</lpage><pub-id pub-id-type="pmid">20584212</pub-id></mixed-citation></ref><ref id="bib49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>PF</given-names></name><name><surname>Kendler</surname><given-names>KS</given-names></name></person-group><year>1999</year><article-title>The genetic epidemiology of smoking</article-title><source>Nicotine Tob Res</source><volume>1</volume><supplement>(Suppl 2</supplement><fpage>S51</fpage><lpage>S57</lpage>discussion S69&#x02013;70.<pub-id pub-id-type="pmid">11768187</pub-id></mixed-citation></ref><ref id="bib50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>The Tobacco and Genetics Consortium</collab></person-group><year>2010</year><article-title>Genome-wide meta-analyses identify multiple loci associated with smoking behavior</article-title><source>Nat Genet</source><volume>42</volume><fpage>441</fpage><lpage>447</lpage><pub-id pub-id-type="pmid">20418890</pub-id></mixed-citation></ref><ref id="bib51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thorgeirsson</surname><given-names>TE</given-names></name><name><surname>Geller</surname><given-names>F</given-names></name><name><surname>Sulem</surname><given-names>P</given-names></name><name><surname>Rafnar</surname><given-names>T</given-names></name><name><surname>Wiste</surname><given-names>A</given-names></name><name><surname>Magnusson</surname><given-names>KP</given-names></name><etal/></person-group><year>2008</year><article-title>A variant associated with nicotine dependence, lung cancer and peripheral arterial disease</article-title><source>Nature</source><volume>452</volume><fpage>638</fpage><lpage>642</lpage><pub-id pub-id-type="pmid">18385739</pub-id></mixed-citation></ref><ref id="bib52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thorgeirsson</surname><given-names>TE</given-names></name><name><surname>Gudbjartsson</surname><given-names>DF</given-names></name><name><surname>Surakka</surname><given-names>I</given-names></name><name><surname>Vink</surname><given-names>JM</given-names></name><name><surname>Amin</surname><given-names>N</given-names></name><name><surname>Geller</surname><given-names>F</given-names></name><etal/></person-group><year>2010</year><article-title>Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior</article-title><source>Nat Genet</source><volume>42</volume><fpage>448</fpage><lpage>453</lpage><pub-id pub-id-type="pmid">20418888</pub-id></mixed-citation></ref><ref id="bib53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warner</surname><given-names>C</given-names></name><name><surname>Shoaib</surname><given-names>M</given-names></name></person-group><year>2005</year><article-title>How does bupropion work as a smoking cessation aid</article-title><source>Addict Biol</source><volume>10</volume><fpage>219</fpage><lpage>231</lpage><pub-id pub-id-type="pmid">16109583</pub-id></mixed-citation></ref><ref id="bib54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xian</surname><given-names>H</given-names></name><name><surname>Scherrer</surname><given-names>JF</given-names></name><name><surname>Madden</surname><given-names>PA</given-names></name><name><surname>Lyons</surname><given-names>MJ</given-names></name><name><surname>Tsuang</surname><given-names>M</given-names></name><name><surname>True</surname><given-names>WR</given-names></name><etal/></person-group><year>2003</year><article-title>The heritability of failed smoking cessation and nicotine withdrawal in twins who smoked and attempted to quit</article-title><source>Nicotine Tob Res</source><volume>5</volume><fpage>245</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">12745498</pub-id></mixed-citation></ref><ref id="bib55"><mixed-citation publication-type="other"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Duan</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Nie</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><etal/></person-group><year>2011</year><article-title>Functionally significant nicotine acetylcholine receptor subunit alpha5 promoter haplotypes are associated with susceptibility to lung cancer in Chinese</article-title><source>Cancer</source>e-pub ahead of print 29 March 2011).</mixed-citation></ref></ref-list><sec sec-type="supplementary-material" id="sup1"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="xob1"><label>Supplementary Table 1</label><media xmlns:xlink="http://www.w3.org/1999/xlink" mimetype="application" mime-subtype="msword" xlink:href="npp2011232x1.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></back><floats-group><fig id="fig1"><label>Figure 1</label><caption><p>Genetic markers most significantly associated with continuous abstinence: (a) varenicline, (b) bupropion.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="npp2011232f1"/></fig><fig id="fig2"><label>Figure 2</label><caption><p>Time to relapse among those who had successfully quit at weeks 9&#x02013;12, all groups combined: (a) rs11606194, (b) rs3758987.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="npp2011232f2"/></fig><table-wrap id="tbl1"><label>Table 1</label><caption><title>Characteristics of Genotyped Patients from the Clinical Trials</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="char" char="("/><col align="char" char="("/><col align="char" char="("/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50">&#x000a0;</th><th align="char" valign="top" char="(" charoff="50"><bold>Varenicline</bold></th><th align="char" valign="top" char="(" charoff="50"><bold>Bupropion</bold></th><th align="char" valign="top" char="(" charoff="50"><bold>Placebo</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Age (SD)</td><td align="char" valign="top" char="(" charoff="50">43.8 (11.1)</td><td align="char" valign="top" char="(" charoff="50">42.7 (12.0)</td><td align="char" valign="top" char="(" charoff="50">42.7 (11.9)</td></tr><tr><td align="left" valign="top" charoff="50">Gender, &#x00025; male</td><td align="char" valign="top" char="(" charoff="50">52</td><td align="char" valign="top" char="(" charoff="50">56</td><td align="char" valign="top" char="(" charoff="50">57</td></tr><tr><td align="left" valign="top" charoff="50">Race, &#x00025; Caucasian</td><td align="char" valign="top" char="(" charoff="50">82</td><td align="char" valign="top" char="(" charoff="50">82</td><td align="char" valign="top" char="(" charoff="50">79</td></tr><tr><td align="left" valign="top" charoff="50">Weight, kg (SD)</td><td align="char" valign="top" char="(" charoff="50">79.7 (16.2)</td><td align="char" valign="top" char="(" charoff="50">79.0 (15.9)</td><td align="char" valign="top" char="(" charoff="50">79.3 (15.6)</td></tr><tr><td align="left" valign="top" charoff="50">Smoking history, CPD (SD)</td><td align="char" valign="top" char="(" charoff="50">22.5 (9.9)</td><td align="char" valign="top" char="(" charoff="50">21.9 (8.7)</td><td align="char" valign="top" char="(" charoff="50">22.3 (9.7)</td></tr><tr><td align="left" valign="top" charoff="50">FTND total score (SD)</td><td align="char" valign="top" char="(" charoff="50">5.34 (2.2)</td><td align="char" valign="top" char="(" charoff="50">5.27 (2.1)</td><td align="char" valign="top" char="(" charoff="50">5.28 (2.0)</td></tr></tbody></table><table-wrap-foot><fn id="t1-fn1"><p>Abbreviations: CPD, cigarettes per day; FTND, Fagerstr&#x000f6;m Test for Nicotine Dependence.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl2"><label>Table 2</label><caption><title>Pharmacogenomics of Continuous Abstinence at Weeks 9&#x02013;12</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="char" char="."/><col align="left"/><col align="center"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="&#x02013;"/><col align="char" char="."/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>SNP</bold></th><th align="char" valign="top" char="." charoff="50"><bold>MAF</bold></th><th align="left" valign="top" charoff="50"><bold>Gene</bold></th><th align="center" valign="top" charoff="50"><bold>Region</bold></th><th align="char" valign="top" char="." charoff="50"><bold>Varenicline <italic>p</italic>-value</bold></th><th align="char" valign="top" char="." charoff="50"><bold>OR</bold></th><th align="char" valign="top" char="&#x02013;" charoff="50"><bold>95&#x00025; CI</bold></th><th align="char" valign="top" char="." charoff="50"><bold><italic>q</italic>-value</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">rs7164594</td><td align="char" valign="top" char="." charoff="50">0.21</td><td align="left" valign="top" charoff="50"><italic>LOC123688</italic></td><td align="center" valign="top" charoff="50">15q25</td><td align="char" valign="top" char="." charoff="50">0.0019</td><td align="char" valign="top" char="." charoff="50">1.76</td><td align="char" valign="top" char="&#x02013;" charoff="50">1.23&#x02013;2.52</td><td align="char" valign="top" char="." charoff="50">0.181</td></tr><tr><td align="left" valign="top" charoff="50">rs3787138</td><td align="char" valign="top" char="." charoff="50">0.13</td><td align="left" valign="top" charoff="50"><italic>CHRNA4</italic></td><td align="center" valign="top" charoff="50">20q13</td><td align="char" valign="top" char="." charoff="50">0.0030</td><td align="char" valign="top" char="." charoff="50">1.89</td><td align="char" valign="top" char="&#x02013;" charoff="50">1.24&#x02013;2.88</td><td align="char" valign="top" char="." charoff="50">0.181</td></tr><tr><td align="left" valign="top" charoff="50">rs6494212</td><td align="char" valign="top" char="." charoff="50">0.30</td><td align="left" valign="top" charoff="50"><italic>CHRNA7</italic></td><td align="center" valign="top" charoff="50">15q13</td><td align="char" valign="top" char="." charoff="50">0.0038</td><td align="char" valign="top" char="." charoff="50">1.58</td><td align="char" valign="top" char="&#x02013;" charoff="50">1.16&#x02013;2.15</td><td align="char" valign="top" char="." charoff="50">0.181</td></tr><tr><td align="left" valign="top" charoff="50">rs3811450</td><td align="char" valign="top" char="." charoff="50">0.07</td><td align="left" valign="top" charoff="50"><italic>CHRNB2</italic></td><td align="center" valign="top" charoff="50">1q21</td><td align="char" valign="top" char="." charoff="50">0.0048</td><td align="char" valign="top" char="." charoff="50">2.52</td><td align="char" valign="top" char="&#x02013;" charoff="50">1.32&#x02013;4.78</td><td align="char" valign="top" char="." charoff="50">0.181</td></tr><tr><td align="left" valign="top" charoff="50">rs2236196</td><td align="char" valign="top" char="." charoff="50">0.27</td><td align="left" valign="top" charoff="50"><italic>CHRNA4</italic></td><td align="center" valign="top" charoff="50">20q13</td><td align="char" valign="top" char="." charoff="50">0.0063</td><td align="char" valign="top" char="." charoff="50">1.54</td><td align="char" valign="top" char="&#x02013;" charoff="50">1.13&#x02013;2.09</td><td align="char" valign="top" char="." charoff="50">0.181</td></tr><tr><td align="left" valign="top" charoff="50">rs4292956</td><td align="char" valign="top" char="." charoff="50">0.07</td><td align="left" valign="top" charoff="50"><italic>CHRNB2</italic></td><td align="center" valign="top" charoff="50">1q21</td><td align="char" valign="top" char="." charoff="50">0.0067</td><td align="char" valign="top" char="." charoff="50">2.44</td><td align="char" valign="top" char="&#x02013;" charoff="50">1.28&#x02013;4.63</td><td align="char" valign="top" char="." charoff="50">0.181</td></tr><tr><td align="left" valign="top" charoff="50">rs518425</td><td align="char" valign="top" char="." charoff="50">0.28</td><td align="left" valign="top" charoff="50"><italic>CHRNA5</italic></td><td align="center" valign="top" charoff="50">15q25</td><td align="char" valign="top" char="." charoff="50">0.0071</td><td align="char" valign="top" char="." charoff="50">1.62</td><td align="char" valign="top" char="&#x02013;" charoff="50">1.14&#x02013;2.31</td><td align="char" valign="top" char="." charoff="50">0.181</td></tr><tr><td align="left" valign="top" charoff="50">rs6062899</td><td align="char" valign="top" char="." charoff="50">0.18</td><td align="left" valign="top" charoff="50"><italic>CHRNA4</italic></td><td align="center" valign="top" charoff="50">20q13</td><td align="char" valign="top" char="." charoff="50">0.0071</td><td align="char" valign="top" char="." charoff="50">1.63</td><td align="char" valign="top" char="&#x02013;" charoff="50">1.14&#x02013;2.33</td><td align="char" valign="top" char="." charoff="50">0.181</td></tr><tr><td align="left" valign="top" charoff="50">rs2938674</td><td align="char" valign="top" char="." charoff="50">0.21</td><td align="left" valign="top" charoff="50"><italic>IREB2</italic></td><td align="center" valign="top" charoff="50">15q25</td><td align="char" valign="top" char="." charoff="50">0.0095</td><td align="char" valign="top" char="." charoff="50">1.60</td><td align="char" valign="top" char="&#x02013;" charoff="50">1.12&#x02013;2.27</td><td align="char" valign="top" char="." charoff="50">0.196</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50"><bold>Bupropion <italic>p</italic>-value</bold></td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="&#x02013;" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">rs8109525</td><td align="char" valign="top" char="." charoff="50">0.34</td><td align="left" valign="top" charoff="50"><italic>CYP2B6</italic></td><td align="center" valign="top" charoff="50">19q13</td><td align="char" valign="top" char="." charoff="50">0.0008</td><td align="char" valign="top" char="." charoff="50">1.78</td><td align="char" valign="top" char="&#x02013;" charoff="50">1.27&#x02013;2.50</td><td align="char" valign="top" char="." charoff="50">0.120</td></tr><tr><td align="left" valign="top" charoff="50">rs3762528</td><td align="char" valign="top" char="." charoff="50">0.07</td><td align="left" valign="top" charoff="50"><italic>CHRND</italic></td><td align="center" valign="top" charoff="50">2q37</td><td align="char" valign="top" char="." charoff="50">0.0012</td><td align="char" valign="top" char="." charoff="50">2.98</td><td align="char" valign="top" char="&#x02013;" charoff="50">1.54&#x02013;5.77</td><td align="char" valign="top" char="." charoff="50">0.120</td></tr><tr><td align="left" valign="top" charoff="50">rs1808682</td><td align="char" valign="top" char="." charoff="50">0.25</td><td align="left" valign="top" charoff="50"><italic>CYP2B6</italic></td><td align="center" valign="top" charoff="50">19q13</td><td align="char" valign="top" char="." charoff="50">0.0030</td><td align="char" valign="top" char="." charoff="50">1.70</td><td align="char" valign="top" char="&#x02013;" charoff="50">1.20&#x02013;2.41</td><td align="char" valign="top" char="." charoff="50">0.154</td></tr><tr><td align="left" valign="top" charoff="50">rs6725786</td><td align="char" valign="top" char="." charoff="50">0.10</td><td align="left" valign="top" charoff="50"><italic>CHRND</italic></td><td align="center" valign="top" charoff="50">2q37</td><td align="char" valign="top" char="." charoff="50">0.0036</td><td align="char" valign="top" char="." charoff="50">2.23</td><td align="char" valign="top" char="&#x02013;" charoff="50">1.30&#x02013;3.84</td><td align="char" valign="top" char="." charoff="50">0.154</td></tr><tr><td align="left" valign="top" charoff="50">rs1042389</td><td align="char" valign="top" char="." charoff="50">0.20</td><td align="left" valign="top" charoff="50"><italic>CYP2B6</italic></td><td align="center" valign="top" charoff="50">19q13</td><td align="char" valign="top" char="." charoff="50">0.0038</td><td align="char" valign="top" char="." charoff="50">1.90</td><td align="char" valign="top" char="&#x02013;" charoff="50">1.23&#x02013;2.92</td><td align="char" valign="top" char="." charoff="50">0.154</td></tr><tr><td align="left" valign="top" charoff="50">rs2113103</td><td align="char" valign="top" char="." charoff="50">0.16</td><td align="left" valign="top" charoff="50"><italic>CYP2B6</italic></td><td align="center" valign="top" charoff="50">19q13</td><td align="char" valign="top" char="." charoff="50">0.0049</td><td align="char" valign="top" char="." charoff="50">1.82</td><td align="char" valign="top" char="&#x02013;" charoff="50">1.20&#x02013;2.76</td><td align="char" valign="top" char="." charoff="50">0.167</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50"><bold>Overall <italic>p</italic>-value</bold></td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="&#x02013;" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">rs8109525</td><td align="char" valign="top" char="." charoff="50">0.34</td><td align="left" valign="top" charoff="50"><italic>CYP2B6</italic></td><td align="center" valign="top" charoff="50">19q13</td><td align="char" valign="top" char="." charoff="50">0.0011</td><td align="char" valign="top" char="." charoff="50">1.37</td><td align="char" valign="top" char="&#x02013;" charoff="50">1.13&#x02013;1.66</td><td align="char" valign="top" char="." charoff="50">0.111</td></tr><tr><td align="left" valign="top" charoff="50">rs1808682</td><td align="char" valign="top" char="." charoff="50">0.25</td><td align="left" valign="top" charoff="50"><italic>CYP2B6</italic></td><td align="center" valign="top" charoff="50">19q13</td><td align="char" valign="top" char="." charoff="50">0.0013</td><td align="char" valign="top" char="." charoff="50">1.40</td><td align="char" valign="top" char="&#x02013;" charoff="50">1.14&#x02013;1.72</td><td align="char" valign="top" char="." charoff="50">0.111</td></tr><tr><td align="left" valign="top" charoff="50">rs2014141</td><td align="char" valign="top" char="." charoff="50">0.40</td><td align="left" valign="top" charoff="50"><italic>CYP2B6</italic></td><td align="center" valign="top" charoff="50">19q13</td><td align="char" valign="top" char="." charoff="50">0.0020</td><td align="char" valign="top" char="." charoff="50">0.75</td><td align="char" valign="top" char="&#x02013;" charoff="50">0.62&#x02013;0.90</td><td align="char" valign="top" char="." charoff="50">0.115</td></tr><tr><td align="left" valign="top" charoff="50">rs2113103</td><td align="char" valign="top" char="." charoff="50">0.16</td><td align="left" valign="top" charoff="50"><italic>CYP2B6</italic></td><td align="center" valign="top" charoff="50">19q13</td><td align="char" valign="top" char="." charoff="50">0.0030</td><td align="char" valign="top" char="." charoff="50">1.43</td><td align="char" valign="top" char="&#x02013;" charoff="50">1.13&#x02013;1.82</td><td align="char" valign="top" char="." charoff="50">0.129</td></tr><tr><td align="left" valign="top" charoff="50">rs6010918</td><td align="char" valign="top" char="." charoff="50">0.05</td><td align="left" valign="top" charoff="50"><italic>CHRNA4</italic></td><td align="center" valign="top" charoff="50">20q13</td><td align="char" valign="top" char="." charoff="50">0.0048</td><td align="char" valign="top" char="." charoff="50">1.75</td><td align="char" valign="top" char="&#x02013;" charoff="50">1.19&#x02013;2.59</td><td align="char" valign="top" char="." charoff="50">0.167</td></tr></tbody></table><table-wrap-foot><fn id="t2-fn1"><p>Abbreviations: CI, confidence interval; MAF, minor allele frequency; OR, odds ratio; SNP, single-nucleotide polymorphism.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl3"><label>Table 3</label><caption><title>Pharmacogenomics of Continuous Abstinence at Weeks 9&#x02013;52</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="char" char="."/><col align="left"/><col align="center"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="&#x02013;"/><col align="char" char="."/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>SNP</bold></th><th align="char" valign="top" char="." charoff="50"><bold>MAF</bold></th><th align="left" valign="top" charoff="50"><bold>Gene</bold></th><th align="center" valign="top" charoff="50"><bold>Region</bold></th><th align="char" valign="top" char="." charoff="50"><bold>Bupropion <italic>p</italic>-value</bold></th><th align="char" valign="top" char="." charoff="50"><bold>OR</bold></th><th align="char" valign="top" char="&#x02013;" charoff="50"><bold>95&#x00025; CI</bold></th><th align="char" valign="top" char="." charoff="50"><bold><italic>q</italic>-value</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">rs1808682</td><td align="char" valign="top" char="." charoff="50">0.251</td><td align="left" valign="top" charoff="50"><italic>CYP2B6</italic></td><td align="center" valign="top" charoff="50">19q13</td><td align="char" valign="top" char="." charoff="50">0.00008</td><td align="char" valign="top" char="." charoff="50">2.27</td><td align="char" valign="top" char="&#x02013;" charoff="50">1.51&#x02013;3.40</td><td align="char" valign="top" char="." charoff="50">0.019</td></tr><tr><td align="left" valign="top" charoff="50">rs1042389</td><td align="char" valign="top" char="." charoff="50">0.201</td><td align="left" valign="top" charoff="50"><italic>CYP2B6</italic></td><td align="center" valign="top" charoff="50">19q13</td><td align="char" valign="top" char="." charoff="50">0.0003</td><td align="char" valign="top" char="." charoff="50">2.49</td><td align="char" valign="top" char="&#x02013;" charoff="50">1.52&#x02013;4.09</td><td align="char" valign="top" char="." charoff="50">0.036</td></tr><tr><td align="left" valign="top" charoff="50">rs2113103</td><td align="char" valign="top" char="." charoff="50">0.156</td><td align="left" valign="top" charoff="50"><italic>CYP2B6</italic></td><td align="center" valign="top" charoff="50">19q13</td><td align="char" valign="top" char="." charoff="50">0.0010</td><td align="char" valign="top" char="." charoff="50">2.16</td><td align="char" valign="top" char="&#x02013;" charoff="50">1.36&#x02013;3.43</td><td align="char" valign="top" char="." charoff="50">0.087</td></tr><tr><td align="left" valign="top" charoff="50">rs8100458</td><td align="char" valign="top" char="." charoff="50">0.339</td><td align="left" valign="top" charoff="50"><italic>CYP2B6</italic></td><td align="center" valign="top" charoff="50">19q13</td><td align="char" valign="top" char="." charoff="50">0.0028</td><td align="char" valign="top" char="." charoff="50">1.82</td><td align="char" valign="top" char="&#x02013;" charoff="50">1.23&#x02013;2.70</td><td align="char" valign="top" char="." charoff="50">0.180</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50"><bold>Overall <italic>p</italic>-value</bold></td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="&#x02013;" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">rs1808682</td><td align="char" valign="top" char="." charoff="50">0.251</td><td align="left" valign="top" charoff="50"><italic>CYP2B6</italic></td><td align="center" valign="top" charoff="50">19q13</td><td align="char" valign="top" char="." charoff="50">0.0001</td><td align="char" valign="top" char="." charoff="50">1.58</td><td align="char" valign="top" char="&#x02013;" charoff="50">1.25&#x02013;1.99</td><td align="char" valign="top" char="." charoff="50">0.019</td></tr><tr><td align="left" valign="top" charoff="50">rs11606194</td><td align="char" valign="top" char="." charoff="50">0.076</td><td align="left" valign="top" charoff="50"><italic>HTR3B</italic></td><td align="center" valign="top" charoff="50">11q23</td><td align="char" valign="top" char="." charoff="50">0.0023</td><td align="char" valign="top" char="." charoff="50">0.47</td><td align="char" valign="top" char="&#x02013;" charoff="50">0.29&#x02013;0.76</td><td align="char" valign="top" char="." charoff="50">0.197</td></tr><tr><td align="left" valign="top" charoff="50">rs892216</td><td align="char" valign="top" char="." charoff="50">0.348</td><td align="left" valign="top" charoff="50"><italic>CYP2B6</italic></td><td align="center" valign="top" charoff="50">19q13</td><td align="char" valign="top" char="." charoff="50">0.0042</td><td align="char" valign="top" char="." charoff="50">1.37</td><td align="char" valign="top" char="&#x02013;" charoff="50">1.11&#x02013;1.70</td><td align="char" valign="top" char="." charoff="50">0.197</td></tr><tr><td align="left" valign="top" charoff="50">rs7123164</td><td align="char" valign="top" char="." charoff="50">0.115</td><td align="left" valign="top" charoff="50"><italic>CHRNA10</italic></td><td align="center" valign="top" charoff="50">11p15</td><td align="char" valign="top" char="." charoff="50">0.0050</td><td align="char" valign="top" char="." charoff="50">1.55</td><td align="char" valign="top" char="&#x02013;" charoff="50">1.14&#x02013;2.11</td><td align="char" valign="top" char="." charoff="50">0.197</td></tr><tr><td align="left" valign="top" charoff="50">rs7255616</td><td align="char" valign="top" char="." charoff="50">0.067</td><td align="left" valign="top" charoff="50"><italic>CYP2A6</italic></td><td align="center" valign="top" charoff="50">19q13</td><td align="char" valign="top" char="." charoff="50">0.0057</td><td align="char" valign="top" char="." charoff="50">1.69</td><td align="char" valign="top" char="&#x02013;" charoff="50">1.16&#x02013;2.45</td><td align="char" valign="top" char="." charoff="50">0.197</td></tr></tbody></table><table-wrap-foot><fn id="t3-fn1"><p>Abbreviations: CI, confidence interval; MAF, minor allele frequency; OR, odds ratio; SNP, single-nucleotide polymorphism.</p></fn><fn id="t3-fn2"><p>rs8109525, shown in <xref ref-type="fig" rid="fig1">Figure 1</xref>, is in strong LD with both rs8100458 and rs892216 (<italic>r</italic><sup>2</sup>&#x0003e;0.95).</p></fn><fn id="t3-fn3"><p>No SNPs were associated with continuous abstinence in patients receiving varenicline.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl4"><label>Table 4</label><caption><title>Loci Associated With Relapse During Weeks 12&#x02013;52, Among Those who had Successfully Quit at Weeks 9&#x02013;12, All Groups Combined (<italic>n</italic>=420)</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="char" char="."/><col align="left"/><col align="center"/><col align="char" char="."/><col align="char" char="."/><col align="char" char="&#x02013;"/><col align="char" char="."/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>SNP</bold></th><th align="char" valign="top" char="." charoff="50"><bold>MAF</bold></th><th align="left" valign="top" charoff="50"><bold>Gene</bold></th><th align="center" valign="top" charoff="50"><bold>Region</bold></th><th align="char" valign="top" char="." charoff="50"><bold><italic>p</italic>-value</bold></th><th align="char" valign="top" char="." charoff="50"><bold>HR</bold></th><th align="char" valign="top" char="&#x02013;" charoff="50"><bold>95&#x00025; CI</bold></th><th align="char" valign="top" char="." charoff="50"><bold><italic>q</italic>-value</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">rs11606194</td><td align="char" valign="top" char="." charoff="50">0.076</td><td align="left" valign="top" charoff="50"><italic>HTR3B</italic></td><td align="center" valign="top" charoff="50">11q23</td><td align="char" valign="top" char="." charoff="50">1.53E&#x02013;05</td><td align="char" valign="top" char="." charoff="50">1.97</td><td align="char" valign="top" char="&#x02013;" charoff="50">1.45&#x02013;2.68</td><td align="char" valign="top" char="." charoff="50">0.003</td></tr><tr><td align="left" valign="top" charoff="50">rs3758987</td><td align="char" valign="top" char="." charoff="50">0.271</td><td align="left" valign="top" charoff="50"><italic>HTR3B</italic></td><td align="center" valign="top" charoff="50">11q23</td><td align="char" valign="top" char="." charoff="50">0.0006</td><td align="char" valign="top" char="." charoff="50">1.46</td><td align="char" valign="top" char="&#x02013;" charoff="50">1.18&#x02013;1.81</td><td align="char" valign="top" char="." charoff="50">0.049</td></tr><tr><td align="left" valign="top" charoff="50">rs11607240</td><td align="char" valign="top" char="." charoff="50">0.074</td><td align="left" valign="top" charoff="50"><italic>HTR3A</italic></td><td align="center" valign="top" charoff="50">11q23</td><td align="char" valign="top" char="." charoff="50">0.0015</td><td align="char" valign="top" char="." charoff="50">1.65</td><td align="char" valign="top" char="&#x02013;" charoff="50">1.21&#x02013;2.25</td><td align="char" valign="top" char="." charoff="50">0.084</td></tr></tbody></table><table-wrap-foot><fn id="t4-fn1"><p>Abbreviations: CI, confidence interval; HR, hazard ratio; MAF, minor allele frequency; SNP, single-nucleotide polymorphism.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl5"><label>Table 5</label><caption><title>Nausea Pharmacogenomics, Overall</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="char" char="."/><col align="left"/><col align="center"/><col align="char" char="."/><col align="char" char="."/><col align="center"/><col align="char" char="."/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>SNP</bold></th><th align="char" valign="top" char="." charoff="50"><bold>MAF</bold></th><th align="left" valign="top" charoff="50"><bold>Gene</bold></th><th align="center" valign="top" charoff="50"><bold>Region</bold></th><th align="char" valign="top" char="." charoff="50"><bold><italic>p</italic>-value</bold></th><th align="char" valign="top" char="." charoff="50"><bold>OR</bold></th><th align="center" valign="top" charoff="50"><bold>95&#x00025; CI</bold></th><th align="char" valign="top" char="." charoff="50"><bold><italic>q</italic>-value</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">rs6495309</td><td align="char" valign="top" char="." charoff="50">0.205</td><td align="left" valign="top" charoff="50"><italic>CHRNB4</italic></td><td align="center" valign="top" charoff="50">15q25</td><td align="char" valign="top" char="." charoff="50">4.04E&#x02013;05</td><td align="char" valign="top" char="." charoff="50">0.50</td><td align="center" valign="top" charoff="50">0.36&#x02013;0.70</td><td align="char" valign="top" char="." charoff="50">0.007</td></tr><tr><td align="left" valign="top" charoff="50">rs4887072</td><td align="char" valign="top" char="." charoff="50">0.216</td><td align="left" valign="top" charoff="50"><italic>CHRNB4</italic></td><td align="center" valign="top" charoff="50">15q25</td><td align="char" valign="top" char="." charoff="50">0.0002</td><td align="char" valign="top" char="." charoff="50">0.55</td><td align="char" valign="top" char="&#x02013;" charoff="50">0.40&#x02013;0.75</td><td align="char" valign="top" char="." charoff="50">0.015</td></tr><tr><td align="left" valign="top" charoff="50">rs1878399</td><td align="char" valign="top" char="." charoff="50">0.424</td><td align="left" valign="top" charoff="50"><italic>CHRNA3</italic></td><td align="center" valign="top" charoff="50">15q25</td><td align="char" valign="top" char="." charoff="50">0.0012</td><td align="char" valign="top" char="." charoff="50">1.48</td><td align="char" valign="top" char="&#x02013;" charoff="50">1.17&#x02013;1.87</td><td align="char" valign="top" char="." charoff="50">0.066</td></tr><tr><td align="left" valign="top" charoff="50">rs1190449</td><td align="char" valign="top" char="." charoff="50">0.447</td><td align="left" valign="top" charoff="50"><italic>CHRNG</italic></td><td align="center" valign="top" charoff="50">2q37</td><td align="char" valign="top" char="." charoff="50">0.0021</td><td align="char" valign="top" char="." charoff="50">1.42</td><td align="char" valign="top" char="&#x02013;" charoff="50">1.13&#x02013;1.77</td><td align="char" valign="top" char="." charoff="50">0.092</td></tr><tr><td align="left" valign="top" charoff="50">rs6741278</td><td align="char" valign="top" char="." charoff="50">0.369</td><td align="left" valign="top" charoff="50"><italic>CHRNG</italic></td><td align="center" valign="top" charoff="50">2q37</td><td align="char" valign="top" char="." charoff="50">0.0033</td><td align="char" valign="top" char="." charoff="50">0.69</td><td align="center" valign="top" charoff="50">0.54&#x02013;0.88</td><td align="char" valign="top" char="." charoff="50">0.099</td></tr><tr><td align="left" valign="top" charoff="50">rs578776</td><td align="char" valign="top" char="." charoff="50">0.273</td><td align="left" valign="top" charoff="50"><italic>CHRNA3</italic></td><td align="center" valign="top" charoff="50">15q25</td><td align="char" valign="top" char="." charoff="50">0.0039</td><td align="char" valign="top" char="." charoff="50">0.67</td><td align="char" valign="top" char="&#x02013;" charoff="50">0.51&#x02013;0.88</td><td align="char" valign="top" char="." charoff="50">0.099</td></tr><tr><td align="left" valign="top" charoff="50">rs595374</td><td align="char" valign="top" char="." charoff="50">0.215</td><td align="left" valign="top" charoff="50"><italic>SLC22A2</italic></td><td align="center" valign="top" charoff="50">6q25</td><td align="char" valign="top" char="." charoff="50">0.0040</td><td align="char" valign="top" char="." charoff="50">0.64</td><td align="char" valign="top" char="&#x02013;" charoff="50">0.48&#x02013;0.87</td><td align="char" valign="top" char="." charoff="50">0.099</td></tr><tr><td align="left" valign="top" charoff="50">rs4243083</td><td align="char" valign="top" char="." charoff="50">0.416</td><td align="left" valign="top" charoff="50"><italic>PSMA4</italic></td><td align="center" valign="top" charoff="50">15q25</td><td align="char" valign="top" char="." charoff="50">0.0049</td><td align="char" valign="top" char="." charoff="50">1.40</td><td align="char" valign="top" char="&#x02013;" charoff="50">1.11&#x02013;1.77</td><td align="char" valign="top" char="." charoff="50">0.105</td></tr><tr><td align="left" valign="top" charoff="50">rs684513</td><td align="char" valign="top" char="." charoff="50">0.197</td><td align="left" valign="top" charoff="50"><italic>CHRNA5</italic></td><td align="center" valign="top" charoff="50">15q25</td><td align="char" valign="top" char="." charoff="50">0.0076</td><td align="char" valign="top" char="." charoff="50">0.65</td><td align="char" valign="top" char="&#x02013;" charoff="50">0.48&#x02013;0.89</td><td align="char" valign="top" char="." charoff="50">0.138</td></tr><tr><td align="left" valign="top" charoff="50">rs12899425</td><td align="char" valign="top" char="." charoff="50">0.274</td><td align="left" valign="top" charoff="50"><italic>IREB2</italic></td><td align="center" valign="top" charoff="50">15q25</td><td align="char" valign="top" char="." charoff="50">0.0087</td><td align="char" valign="top" char="." charoff="50">1.39</td><td align="char" valign="top" char="&#x02013;" charoff="50">1.09&#x02013;1.77</td><td align="char" valign="top" char="." charoff="50">0.138</td></tr><tr><td align="left" valign="top" charoff="50">rs2869546</td><td align="char" valign="top" char="." charoff="50">0.370</td><td align="left" valign="top" charoff="50"><italic>CHRNA3</italic></td><td align="center" valign="top" charoff="50">15q25</td><td align="char" valign="top" char="." charoff="50">0.0088</td><td align="char" valign="top" char="." charoff="50">1.37</td><td align="char" valign="top" char="&#x02013;" charoff="50">1.08&#x02013;1.73</td><td align="char" valign="top" char="." charoff="50">0.138</td></tr><tr><td align="left" valign="top" charoff="50">rs11899983</td><td align="char" valign="top" char="." charoff="50">0.437</td><td align="left" valign="top" charoff="50"><italic>CHRNG</italic></td><td align="center" valign="top" charoff="50">2q37</td><td align="char" valign="top" char="." charoff="50">0.0113</td><td align="char" valign="top" char="." charoff="50">1.34</td><td align="char" valign="top" char="&#x02013;" charoff="50">1.07&#x02013;1.68</td><td align="char" valign="top" char="." charoff="50">0.157</td></tr><tr><td align="left" valign="top" charoff="50">rs17406522</td><td align="char" valign="top" char="." charoff="50">0.072</td><td align="left" valign="top" charoff="50"><italic>IREB2</italic></td><td align="center" valign="top" charoff="50">15q25</td><td align="char" valign="top" char="." charoff="50">0.0125</td><td align="char" valign="top" char="." charoff="50">1.67</td><td align="char" valign="top" char="&#x02013;" charoff="50">1.12&#x02013;2.50</td><td align="char" valign="top" char="." charoff="50">0.157</td></tr><tr><td align="left" valign="top" charoff="50">rs12443170</td><td align="char" valign="top" char="." charoff="50">0.126</td><td align="left" valign="top" charoff="50"><italic>CHRNA3</italic></td><td align="center" valign="top" charoff="50">15q25</td><td align="char" valign="top" char="." charoff="50">0.0128</td><td align="char" valign="top" char="." charoff="50">0.62</td><td align="char" valign="top" char="&#x02013;" charoff="50">0.42&#x02013;0.90</td><td align="char" valign="top" char="." charoff="50">0.157</td></tr><tr><td align="left" valign="top" charoff="50">rs12441998</td><td align="char" valign="top" char="." charoff="50">0.199</td><td align="left" valign="top" charoff="50"><italic>CHRNB4</italic></td><td align="center" valign="top" charoff="50">15q25</td><td align="char" valign="top" char="." charoff="50">0.0151</td><td align="char" valign="top" char="." charoff="50">0.68</td><td align="char" valign="top" char="&#x02013;" charoff="50">0.50&#x02013;0.93</td><td align="char" valign="top" char="." charoff="50">0.173</td></tr></tbody></table><table-wrap-foot><fn id="t5-fn1"><p>Abbreviations: CI, confidence interval; OR, odds ratio; SNP, single-nucleotide polymorphism.</p></fn></table-wrap-foot></table-wrap><boxed-text id="box1"><caption><title>Box 1 Varenicline Clinical Studies Included in the Pharmacogenetics Analysis</title></caption><p><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="npp2011232i1.jpg"/></p></boxed-text><boxed-text id="box2"><caption><title>Box 2 Candidate Gene List</title></caption><p><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="npp2011232i2.jpg"/></p></boxed-text></floats-group></article>